0001512922 2026-04-01 2026-06-30 0001512922 2026-08-14 0001512922 2026-06-30 0001512922 2026-03-31 0001512922 us-gaap:PreferredClassBMember 2026-06-30 0001512922 us-gaap:PreferredClassBMember 2026-03-31 0001512922 us-gaap:SeriesBPreferredStockMember 2026-06-30 0001512922 us-gaap:SeriesBPreferredStockMember 2026-03-31 0001512922 2025-04-01 2025-06-30 0001512922 us-gaap:CommonStockMember 2026-03-31 0001512922 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-03-31 0001512922 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-03-31 0001512922 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0001512922 PETV:CommonStockToBeIssuedMember 2026-03-31 0001512922 us-gaap:RetainedEarningsMember 2026-03-31 0001512922 us-gaap:CommonStockMember 2025-03-31 0001512922 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0001512922 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-03-31 0001512922 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001512922 us-gaap:RetainedEarningsMember 2025-03-31 0001512922 2025-03-31 0001512922 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0001512922 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0001512922 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-04-01 2026-06-30 0001512922 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0001512922 PETV:CommonStockToBeIssuedMember 2026-04-01 2026-06-30 0001512922 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0001512922 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001512922 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0001512922 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-04-01 2025-06-30 0001512922 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001512922 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001512922 us-gaap:CommonStockMember 2026-06-30 0001512922 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2026-06-30 0001512922 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2026-06-30 0001512922 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001512922 PETV:CommonStockToBeIssuedMember 2026-06-30 0001512922 us-gaap:RetainedEarningsMember 2026-06-30 0001512922 us-gaap:CommonStockMember 2025-06-30 0001512922 us-gaap:SeriesAPreferredStockMember us-gaap:PreferredStockMember 2025-06-30 0001512922 us-gaap:SeriesBPreferredStockMember us-gaap:PreferredStockMember 2025-06-30 0001512922 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001512922 us-gaap:RetainedEarningsMember 2025-06-30 0001512922 2025-06-30 0001512922 srt:MinimumMember PETV:ProductionAndComputerEquipmentAndFurnitureMember 2026-06-30 0001512922 srt:MaximumMember PETV:ProductionAndComputerEquipmentAndFurnitureMember 2026-06-30 0001512922 PETV:PatentsAndTrademarksMember 2026-06-30 0001512922 PETV:EconomicBenefitsMember 2026-06-30 0001512922 us-gaap:RestrictedStockMember 2026-06-30 0001512922 us-gaap:RestrictedStockMember 2025-06-30 0001512922 PETV:SalesToVedcoMember 2026-04-01 2026-06-30 0001512922 PETV:SalesToVedcoMember 2025-04-01 2025-06-30 0001512922 PETV:ClipperMember 2026-04-01 2026-06-30 0001512922 PETV:ClipperMember 2025-04-01 2025-06-30 0001512922 PETV:SalesToVedcoMember 2026-06-30 0001512922 PETV:SalesToVedcoMember 2026-03-31 0001512922 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-03-31 0001512922 srt:ScenarioPreviouslyReportedMember 2026-03-31 0001512922 srt:ScenarioPreviouslyReportedMember 2025-06-30 0001512922 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2025-06-30 0001512922 srt:ScenarioPreviouslyReportedMember 2026-06-29 0001512922 srt:RevisionOfPriorPeriodReclassificationAdjustmentMember 2026-06-30 0001512922 us-gaap:LeaseholdImprovementsMember 2026-06-30 0001512922 us-gaap:LeaseholdImprovementsMember 2026-03-31 0001512922 us-gaap:EquipmentMember 2026-06-30 0001512922 us-gaap:EquipmentMember 2026-03-31 0001512922 PETV:ResearchAndDevelopmentEquipmentMember 2026-06-30 0001512922 PETV:ResearchAndDevelopmentEquipmentMember 2026-03-31 0001512922 PETV:ComputerEquipmentAndFurnitureMember 2026-06-30 0001512922 PETV:ComputerEquipmentAndFurnitureMember 2026-03-31 0001512922 us-gaap:LicensingAgreementsMember 2025-02-01 2025-02-28 0001512922 us-gaap:LicensingAgreementsMember 2025-02-28 0001512922 2025-08-01 2025-08-31 0001512922 2025-11-01 2025-11-30 0001512922 srt:MinimumMember us-gaap:LicensingAgreementsMember 2025-02-01 2025-02-28 0001512922 srt:MaximumMember us-gaap:LicensingAgreementsMember 2025-02-01 2025-02-28 0001512922 2025-03-28 0001512922 2025-02-28 0001512922 us-gaap:MeasurementInputExpectedDividendPaymentMember 2026-06-30 0001512922 us-gaap:MeasurementInputExpectedDividendPaymentMember 2025-06-30 0001512922 us-gaap:MeasurementInputPriceVolatilityMember 2026-06-30 0001512922 us-gaap:MeasurementInputPriceVolatilityMember 2025-06-30 0001512922 us-gaap:MeasurementInputRiskFreeInterestRateMember 2026-06-30 0001512922 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-06-30 0001512922 us-gaap:MeasurementInputExpectedTermMember 2026-06-30 0001512922 us-gaap:MeasurementInputExpectedTermMember 2025-06-30 0001512922 2025-04-01 2026-03-31 0001512922 us-gaap:LicensingAgreementsMember 2025-09-01 2025-09-30 0001512922 us-gaap:LicensingAgreementsMember us-gaap:CommonStockMember 2025-09-01 2025-09-30 0001512922 us-gaap:LicensingAgreementsMember 2025-09-30 0001512922 srt:MinimumMember us-gaap:LicensingAgreementsMember 2025-09-01 2025-09-30 0001512922 srt:MaximumMember us-gaap:LicensingAgreementsMember 2025-09-01 2025-09-30 0001512922 us-gaap:LicensingAgreementsMember 2026-04-01 2026-06-30 0001512922 us-gaap:LicensingAgreementsMember 2025-04-01 2025-06-30 0001512922 PETV:DigitalLandiaHoldingCorpMember 2026-04-01 2026-06-30 0001512922 PETV:DigitalLandiaHoldingCorpMember 2025-04-01 2025-06-30 0001512922 PETV:TwoSeperatePromissoryNotesMember 2026-02-28 0001512922 PETV:TwoSeperatePromissoryNotesMember 2026-03-31 0001512922 PETV:FirstPromissoryNotesMember 2026-02-26 0001512922 PETV:FirstPromissoryNotesMember 2026-02-26 2026-02-26 0001512922 PETV:SecondPromissoryNotesMember 2026-03-11 0001512922 PETV:SecondPromissoryNotesMember 2026-03-11 2026-03-11 0001512922 PETV:ThirdPromissoryNotesMember 2026-06-22 0001512922 PETV:ThirdPromissoryNotesMember 2026-06-22 2026-06-22 0001512922 PETV:ThreeSeperatePromissoryNotesMember 2026-06-30 0001512922 us-gaap:ConvertibleDebtMember 2024-03-08 0001512922 us-gaap:ConvertibleDebtMember 2024-04-10 0001512922 us-gaap:ConvertibleDebtMember 2024-04-29 2024-04-29 0001512922 us-gaap:ConvertibleDebtMember 2024-04-29 0001512922 us-gaap:CommonStockMember 2024-04-29 2024-04-29 0001512922 us-gaap:ConvertibleDebtMember 2025-03-31 0001512922 us-gaap:ConvertibleDebtMember 2025-06-10 0001512922 us-gaap:MeasurementInputExpectedDividendPaymentMember 2025-03-31 0001512922 us-gaap:MeasurementInputPriceVolatilityMember 2025-03-31 0001512922 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-03-31 0001512922 us-gaap:MeasurementInputExpectedTermMember 2025-03-31 0001512922 2025-10-01 2025-12-31 0001512922 PETV:ConvertiblePromissoryNoteMember 2025-09-30 0001512922 us-gaap:CommonStockMember 2025-09-30 2025-09-30 0001512922 2025-09-30 2025-09-30 0001512922 2025-09-30 0001512922 us-gaap:ConvertibleNotesPayableMember 2026-06-30 0001512922 us-gaap:ConvertibleNotesPayableMember 2026-03-31 0001512922 PETV:ConvertiblePromissoryNoteMember 2026-04-01 2026-06-30 0001512922 PETV:ConvertiblePromissoryNoteMember 2025-04-01 2025-06-30 0001512922 us-gaap:ConvertibleDebtMember 2025-02-14 0001512922 us-gaap:WarrantMember us-gaap:ConvertibleDebtMember 2025-02-14 0001512922 us-gaap:WarrantMember us-gaap:MeasurementInputOfferedPriceMember us-gaap:ConvertibleDebtMember 2025-02-14 0001512922 us-gaap:WarrantMember us-gaap:MeasurementInputSharePriceMember us-gaap:ConvertibleDebtMember 2025-02-14 0001512922 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedTermMember us-gaap:ConvertibleDebtMember 2025-02-14 0001512922 us-gaap:WarrantMember us-gaap:MeasurementInputOptionVolatilityMember us-gaap:ConvertibleDebtMember 2025-02-14 0001512922 us-gaap:WarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember us-gaap:ConvertibleDebtMember 2025-02-14 0001512922 us-gaap:WarrantMember us-gaap:MeasurementInputExpectedDividendRateMember us-gaap:ConvertibleDebtMember 2025-02-14 0001512922 us-gaap:ConvertibleDebtMember 2025-04-01 2025-09-30 0001512922 us-gaap:ConvertibleDebtMember 2025-09-30 0001512922 us-gaap:ConvertibleDebtMember 2026-04-01 2026-06-30 0001512922 us-gaap:ConvertibleDebtMember 2025-04-01 2025-06-30 0001512922 2025-06-30 2025-06-30 0001512922 us-gaap:MeasurementInputSharePriceMember 2025-02-14 0001512922 us-gaap:MeasurementInputSharePriceMember 2025-03-31 0001512922 us-gaap:MeasurementInputSharePriceMember 2025-06-30 0001512922 us-gaap:MeasurementInputConversionPriceMember 2025-02-14 0001512922 us-gaap:MeasurementInputConversionPriceMember 2025-03-31 0001512922 us-gaap:MeasurementInputConversionPriceMember 2025-06-30 0001512922 us-gaap:MeasurementInputExpectedTermMember 2025-02-14 0001512922 us-gaap:MeasurementInputPriceVolatilityMember 2025-02-14 0001512922 us-gaap:MeasurementInputRiskFreeInterestRateMember 2025-02-14 0001512922 us-gaap:MeasurementInputExpectedDividendRateMember 2025-02-14 0001512922 us-gaap:MeasurementInputExpectedDividendRateMember 2025-03-31 0001512922 us-gaap:MeasurementInputExpectedDividendRateMember 2025-06-30 0001512922 2025-12-30 0001512922 2025-12-31 2025-12-31 0001512922 2025-07-01 2026-06-30 0001512922 2017-05-31 0001512922 2017-05-01 2017-05-31 0001512922 PETV:ExtendedLeaseTermToTwoThousandTwentySixMember 2020-01-01 2020-01-31 0001512922 PETV:ExtendedLeaseTermToTwoThousandTwentySixMember 2020-01-31 0001512922 PETV:ExtendedLeaseTermToTwoThousandTwentySixMember 2026-04-01 2026-06-30 0001512922 PETV:ExtendedLeaseTermToTwoThousandTwentySixMember 2025-04-01 2026-03-31 0001512922 PETV:JanuaryTwoThousandTwentyTwoLeaseMember 2022-01-31 0001512922 PETV:JanuaryTwoThousandTwentyTwoLeaseMember 2022-01-01 2022-01-31 0001512922 PETV:JanuaryTwoThousandTwentyTwoLeaseMember 2026-04-01 2026-06-30 0001512922 PETV:JanuaryTwoThousandTwentyTwoLeaseMember 2025-04-01 2026-03-31 0001512922 PETV:JanuaryTenTwoThousandTwentyThreeLeaseMember 2023-01-10 0001512922 PETV:JanuaryTenTwoThousandTwentyThreeLeaseMember 2023-01-10 2023-01-10 0001512922 PETV:JanuaryTenTwoThousandTwentyThreeLeaseMember 2026-04-01 2026-06-30 0001512922 PETV:JanuaryTenTwoThousandTwentyThreeLeaseMember 2025-04-01 2026-03-31 0001512922 PETV:TenYearLeaseAgreementMember 2025-06-30 0001512922 PETV:UnrentedOfficeAreaMember PETV:TenYearLeaseAgreementMember 2026-06-30 0001512922 PETV:NovemberSevenTwoThousandTwentySixMember 2026-06-30 0001512922 PETV:MarchTwoThousandTwentySevenMember 2026-06-30 0001512922 PETV:ExtendedLeaseTermToTwoThousandTwentySixMember 2026-06-30 0001512922 PETV:TwoThousandAndTwentyEquityIncentivePlanMember 2020-07-10 0001512922 PETV:AmendedPlanMember 2022-10-13 0001512922 PETV:AmendedPlanMember 2022-10-14 0001512922 PETV:AmendedPlanMember 2026-06-30 0001512922 us-gaap:RestrictedStockMember us-gaap:PrivatePlacementMember 2026-03-01 2026-03-31 0001512922 us-gaap:RestrictedStockMember us-gaap:PrivatePlacementMember 2026-03-31 0001512922 2026-04-20 2026-04-20 0001512922 us-gaap:RestrictedStockMember us-gaap:PrivatePlacementMember 2026-06-01 2026-06-30 0001512922 us-gaap:RestrictedStockMember us-gaap:PrivatePlacementMember 2026-06-30 0001512922 2026-06-30 2026-06-30 0001512922 us-gaap:SeriesBPreferredStockMember PETV:SubscriptionAgreementsMember 2025-03-26 0001512922 PETV:SubscriptionAgreementsMember 2025-03-26 2025-03-26 0001512922 us-gaap:InvestorMember PETV:SubscriptionAgreementsMember 2025-03-26 2025-03-26 0001512922 2026-04-01 2026-04-30 0001512922 2026-06-01 2026-06-30 0001512922 2026-04-30 0001512922 PETV:ServiceProviderMember 2026-06-01 2026-06-30 0001512922 PETV:EmployeesMember 2026-04-01 2026-06-30 0001512922 us-gaap:SeriesBPreferredStockMember 2026-04-01 2026-04-30 0001512922 us-gaap:SeriesBPreferredStockMember 2026-04-30 2026-04-30 0001512922 srt:BoardOfDirectorsChairmanMember 2026-04-01 2026-04-30 0001512922 us-gaap:EmployeeStockOptionMember 2026-04-01 2026-06-30 0001512922 us-gaap:EmployeeStockOptionMember 2025-04-01 2026-03-31 0001512922 us-gaap:EmployeeStockOptionMember 2025-04-01 2025-06-30 0001512922 us-gaap:EmployeeStockOptionMember 2026-06-30 0001512922 PETV:ConsultingAgreementMember 2026-06-30 0001512922 PETV:ConsultingAgreementMember 2026-04-01 2026-06-30 0001512922 us-gaap:WarrantMember 2026-06-30 0001512922 srt:MinimumMember us-gaap:WarrantMember 2026-03-31 0001512922 srt:MaximumMember us-gaap:WarrantMember 2026-03-31 0001512922 us-gaap:WarrantMember 2026-04-01 2026-06-30 0001512922 srt:MinimumMember us-gaap:WarrantMember 2025-04-01 2026-03-31 0001512922 srt:MaximumMember us-gaap:WarrantMember 2025-04-01 2026-03-31 0001512922 us-gaap:WarrantMember 2025-04-01 2026-03-31 0001512922 us-gaap:WarrantMember 2026-03-31 0001512922 PETV:SingleReportableSegmentMember 2026-04-01 2026-06-30 0001512922 us-gaap:OperatingSegmentsMember 2026-04-01 2026-06-30 0001512922 us-gaap:OperatingSegmentsMember 2025-04-01 2025-06-30 0001512922 PETV:DigitalLandiaCorpMember PETV:StrategicAllianceAgreementMember 2025-03-31 0001512922 PETV:RestrictedCommonStockMember PETV:StrategicAllianceAgreementMember 2025-03-01 2025-03-31 0001512922 PETV:DigitalLandiaCorpMember 2025-03-31 0001512922 PETV:StrategicAllianceAgreementMember 2025-03-01 2025-03-31 0001512922 us-gaap:WarrantMember PETV:DigitalLandiaHoldingCorpMember 2025-03-31 0001512922 PETV:DigitalLandiaHoldingCorpMember 2026-06-30 0001512922 PETV:DigitalLandiaHoldingCorpMember 2026-04-01 2026-06-30 0001512922 us-gaap:SeriesBPreferredStockMember us-gaap:SubsequentEventMember 2026-07-01 2026-07-31 0001512922 us-gaap:SubsequentEventMember us-gaap:EmployeeStockMember 2026-07-01 2026-07-31 0001512922 us-gaap:SubsequentEventMember 2026-07-09 2026-07-09 0001512922 us-gaap:SubsequentEventMember 2026-07-24 2026-07-24 0001512922 us-gaap:SubsequentEventMember 2026-07-27 2026-07-27 0001512922 us-gaap:SubsequentEventMember 2026-08-07 2026-08-11 0001512922 us-gaap:SubsequentEventMember 2026-08-11 2026-08-11 0001512922 us-gaap:SubsequentEventMember 2026-08-13 2026-08-13 iso4217:USD shares iso4217:USD shares pure utr:sqft PETV:Segment PETV:Token false Q1 2027 --03-31 0001512922

10-Q true 2026-06-30 false 001-40715 PetVivo Holdings, Inc. NV 99-0363559 5151 Edina Industrial Blvd Suite 575 Edina MN 55439 (952) 405-6216 Common Stock, par value $0.001 PETV Yes Yes Non-accelerated Filer true true false false 0.001 37950495

122633

200782

83792

100843

600000

451334

538366

283260

269930

941019

1709921

447089

448881

38654

54711

20000

20509

1059889 1179889

150000

12830

1281373

1417939

2669481

3576741

453291

547421

344911

453713

38654

54711

476456 321447

1313312

1377292

1313312

1377292

0.001

20000000

5000000

5000

0.001

250000000

37594245

35849919

37595

35850

48000 649750

104316968

102821355

-103051394

-101312506

1356169

2199449

2669481

3576741

337572

297500

114255

110774

223317

186726

631305

621712

233419

340513

967442

1068818

1832166

2031043

-1608849

-1844317

-149125

-320404

111518

13099

5039

121808

-5039

-466720

-1613888

-2311037

-1613888

-2311037

125000

28603

-1738888

-2339640

-0.05

-0.10

37055261

24302790

35849919

35850

5000000

5000

102821355

649750

-101312506

2199449

937500

938

749062

-600000

150000

200000

200

159800

160000

430652

431

329794

-49750

280475

48000 48000

125000

176174 176 124824 125000

132133

-1613888

37594245

37595

5000000

5000

104316968

48000

-103051394

1356169

24181537

24182

3045000

3045

5000000

5000

95385511

-91198490

4219248

60000

40360

40420

8000 8 5992 6000 70000 70 139930 140000

133197

82657

-82

28603

768493

-2311037

24402194

24402

3045000

3045

5000000

5000

96473401

-93538130

2967718

-1613888

-2311037

460609

133197

134671

117890

16057

15722

320404

-149125

66259

160000 40420

13330

-56076

-17051

-34625

-87032

205838

-202933

-87996

-16057

-15722

5009

53120

-965779

-1633755

12370

-12370

600000

150000

4400000

160000

140000

150000

12000

2090

900000

4709910

-78149

3076155

200782

227689

122633

3303844

2635

161000 -859504 150 125000 301558 160000

<p id="xdx_809_eus-gaap--OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_zvxswOpBBckd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES AND ORGANIZATION (A) Organization and Description PetVivo Holdings, Inc. was incorporated in Nevada under its former name in 2009 and entered its current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in PetVivo, Inc. becoming a wholly owned subsidiary of PetVivo Holdings, Inc. In April 2017, PetVivo Holdings, Inc. acquired another Minnesota corporation, Gel-Del Technologies, Inc., through a statutory merger, which is also a wholly-owned subsidiary of PetVivo Holdings, Inc. In April 2025, PetVivo Holdings, Inc. changed the name of its wholly-owned subsidiary PetVivo, Inc. to PetVivo Animal Health, Inc. to better reflect the industry in which PetVivo Holdings, Inc. sells its products. The Company is in the business of licensing and commercializing our proprietary medical devices and biomaterials for the treatment and/or management of afflictions and diseases in animals, initially for dogs and horses. The Company began commercialization of its lead product Spryng® with OsteoCushion® Technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses in September 2021. The Company has a pipeline of additional products for the treatment of animals in various stages of development. The Company currently has six (6) U.S. and four (4) foreign patents issued, with two (2) additional patent applications pending with the United States Patent and Trademark Office. The patents protect the Company’s biomaterials, products, production processes and methods of use. In February 2025, The Company signed an exclusive licensing agreement with VetStem, Inc. to market and sell their PrecisePRP™ (Platelet-Rich Plasma) product for both canine and equine. On July 24, 2026, the Company terminated the licensing agreement with VetStem, Inc. The Company’s operations are conducted from its headquarter facilities in suburban Minneapolis, Minnesota with an outsourced distribution location in St. Joseph, Missouri. (B) Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (US GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X and ASC 270-10-50. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete annual financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the interim periods presented are not necessarily indicative of the results that may be expected for the full fiscal year. These interim condensed financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the company’s annual report on Form 10-K for the fiscal year ended March 31, 2026. Certain prior-period amounts have been reclassified to conform to the current-period presentation. These reclassifications had no effect on previously reported net income, total assets, total liabilities, or stockholders’ equity. (C) Principles of Consolidation The accompanying consolidated financial statements include all the accounts of PetVivo Holdings, Inc., and its four wholly owned corporations, Gel-Del Technologies, Inc., PetVivo Animal Health, Inc., Cosmeta Corp and PetVivo AI (collectively, the “Company”). All intercompany transactions have been eliminated upon consolidation. The Company is an emerging growth company as the term is used in The Jumpstart Our Business Startups Act, enacted on April 5, 2012 and has elected to comply with certain reduced public company reporting requirements. (D) Use of Estimates In preparation of the consolidated financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include allowance for credit losses, inventory obsolescence, estimated useful lives and potential impairment of property and equipment and intangibles, estimate of fair value of share-based payments, distributor rebate payable, provision for product returns, right of use lease assets and liabilities and valuation of deferred tax assets. (E) Cash and Cash Equivalents The Company considers all highly-liquid, temporary cash investments with original maturity of three months or less to be cash equivalents. The Company had no cash equivalents at June 30, 2026. (F) Concentration Risk The Company maintains its cash with various financial institutions, which at times may exceed federally insured limits. At June 30, 2026, the Company did not have cash balances in excess of the federally insured limits. (G) Accounts Receivable Accounts receivable is carried at its contractual amounts, less an estimated allowance for credit losses. Management estimates the credit losses using a loss-rate approach based on historical loss information, adjusted for management’s expectations about current and future economic conditions, as the basis to determine expected credit losses. Management exercises significant judgment in determining expected credit losses. Key inputs include macroeconomic factors, industry trends, the creditworthiness of counterparties, historical experience, the financial conditions of the customers, and the amount and age of past due accounts. Management believes that the composition of receivables is consistent with historical conditions as credit terms and practices and the client base has not changed significantly. Receivables are considered past due if full payment is not received by the contractual due date. Past due accounts are generally written off against the allowance for credit losses only after all collection attempts have been exhausted. As of June 30, 2026 and March 31, 2026, the Company had not recorded an allowance for credit losses, as management determined that no allowance was necessary based on its assessment of the collectability of outstanding balances and the credit quality of its customers. (H) Inventory Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (FIFO) method. Inventory consists of raw materials, work-in-process and finished goods. The Company evaluates inventory for excess, and obsolescence based on factors such as current inventory levels, estimated product life cycles, historical and forecasted customer demand, and input from the product development team. When necessary, an inventory write-off is recorded to reduce the carrying value of inventory to its estimated net realizable value. These estimates and assumptions are reviewed quarterly and annually and updated as needed based on the Company’s business plans and market conditions. The Company recorded an inventory write-off of $239,935 as of March 31, 2026, respectively. The inventory write-off is due to an ongoing negotiation of the VetStem licensing agreement whereby the PrecisePRP product has not been selling as originally expected. Therefore, management decided to sell the PrecisePRP product line at a discount, as to reduce the inventory levels, resulting in the Company recording an inventory write-off of $239,935. (I) Property & Equipment Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method (after considering their respective estimated residual values) over the assets estimated useful life of <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionAndComputerEquipmentAndFurnitureMember__srt--RangeAxis__srt--MinimumMember_zo5QNd9RPIp3">3 to <span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionAndComputerEquipmentAndFurnitureMember__srt--RangeAxis__srt--MaximumMember_zObm7NHvIP16" title="Estimated useful life">5 years for production and computer equipment and furniture. Leasehold improvements are depreciated using the straight-line method over the shorter of the estimated useful lives of the improvements or the remaining lease term (including renewal periods that are reasonably certain to be exercised). (J) Patents and Trademarks The Company capitalizes direct costs for the maintenance and advancement of their patents and trademarks and amortizes these costs over the lesser of the useful life of <span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtM_c20260630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zcs3zYB2u8h5" title="Estimated useful life of intangible assets">60 months or the legal life of the patent. The Company evaluates the recoverability of intangible assets periodically by considering events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired. The Company has chosen to amortize over a sixty (60) month period, as the patent assets are expected to generate economic benefits for only five (<span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--EconomicBenefitsMember_zw1sFJ0ok4Sh" title="Estimated useful life of intangible assets">5) years. (K) Loss Per Share The Company calculates earnings (loss) per share (“EPS”) in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260, Earnings Per Share. Basic EPS is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. For the years ended June 30, 2026 and 2025, the Company reported a net loss; therefore, diluted EPS is calculated the same as basic EPS, as the inclusion of all potentially dilutive securities would be anti-dilutive. The following securities were excluded from the calculation of diluted loss per share because their effect would have been anti-dilutive: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options and warrants: 16,110,035 shares (2026); 14,668,813 shares (2025)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Unvested RSUs: <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zRVgLAZ85W7l" title="Unvested restricted stock units">0 shares (2026); <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1uqU5RYdQC5" title="Unvested restricted stock units">205,314 shares (2025)</td></tr> </table> (L) Revenue Recognition The Company recognizes revenue in accordance with FASB ASC 606 “Revenue from Contracts with Customers.” The Company derives revenue from the sale of its pet care products directly to its veterinarian customers in the United States. The Company recognizes revenue when performance obligations under the terms of a contract with the veterinarian customer are satisfied. Product sales occur once control or title is transferred based on the commercial terms. Revenue is recognized upon delivery to the customer, which is when control of these products is transferred and in an amount that reflects the consideration the Company expects to receive for these products. Shipping costs charged to customers are reported as an offset to the respective shipping costs. The Company does not have any significant financing components as payment is received at or shortly after the point of sale. The Company entered into a Distribution Services Agreement (the “Agreement”) with MWI Veterinary Supply Co. (the “Distributor”) on June 17, 2022. Contracts with the Distributor are evidenced by individual executed purchase orders subject to the terms of the Agreement. The contracts consist of a single performance obligation related to the sale of our pet care products. Product sales occur once control or title is transferred based on the commercial terms in the Agreement. Revenue is recognized upon delivery to the Distributor; payment is due within 60 days. The Agreement provides for a distribution fee payable to the Distributor equal to 5% of gross monthly sales payable in 45 days; the distribution fee is netted against revenue. The Agreement provides for a rebate payable to the Distributor based on annual sales volume that is retroactively applied. The rebate is estimated under the expected value method and is netted against revenue. Sales are subject to various right of return provisions; the Company uses an expected value method to estimate returns and has determined that any returns would be immaterial as of June 30, 2026 and March 31, 2026. As a result, there is no return liability recorded. Shipping and handling costs are a fulfillment activity and are reported as cost of sales. In March 2025, the Company mutually terminated its non-exclusive distribution agreement with MWI. Therefore, we have no distribution fees, no rebates and no right of return provisions. As a result, the Company no longer has any distribution fees, rebates or return liabilities recorded during the three months period ending June 30, 2026 and 2025. The balance sheet continues to show a $57,264 rebate liabilities for periods from 2023-2024. Further, there were no new rebate liabilities in the quarter ending June 30, 2026. Assets and liabilities (included in accrued expenses) under the Agreement were as follows: SCHEDULE OF RECOGNIZED REVENUE ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260630_z0R1p7gpuWx5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20260331_zgIoBP0OpJa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--ReceivablesNetCurrent_iI_zHtGfjqugp0l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Accounts receivable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--RebateLiability_iI_z5nr0teFctJi" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Rebate liability</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">57,264</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">57,264</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--DistributionFeePayable_iI_zuTVzRojBAk8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Distribution fee payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,299</td><td style="text-align: left"> </td></tr> </table> We currently don’t have any distributor agreements in place, as of June 30, 2026. Product sales for all domestic shipments into the United States occur once control or title is transferred based on the commercial terms purchase orders. Revenue is recognized upon delivery to the Distributor in the United States, with international shipments, freight terms are FOB our warehouses, as ownership transfers for these international shipments when our product is picked up; payment is due within 30 days for domestic orders and payment-in-advance for international distributors. From time-to-time, we honor returns for short-dated inventory (close to expiration). Inasmuch, sales periodically are subject to returns; the Company uses an expected value method to estimate returns and has determined that any returns would be immaterial as of June 30, 2026 and March 31, 2026. As a result, there is no return liability recorded. Shipping and handling costs are a fulfillment activity and are reported as cost of sales. In December 2024, the Company entered into new wholesale distribution partnerships with Vedco, Inc. (“Vedco”) and Clipper Distributing, LLC (“Clipper”). A distribution service agreement was not signed with either distribution partner. Contracts with both distribution partners are evidenced by individual executed purchase orders. The purchase orders consist of a single performance obligation related to the sale of our pet care products. Product sales occur once control or title is transferred based on the terms in the purchase order. Revenue is recognized upon delivery to the Distributor for domestic shipments, and for international shipments, ownership transfers at the point of freight pickup from our warehouse, at which time we recognize the revenue for these international customers; payment is due within 30 days. Neither distribution partnership provides for a distribution fee payable or a rebate payable. For the three months ended June 30, 2026 and 2025, the Company recognized revenue from product sales to Vedco of $<span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260401__20260630__srt--ProductOrServiceAxis__custom--SalesToVedcoMember_zgAVhKTfgGA9" title="Revenue from contract with customer">234,623 and $<span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20250401__20250630__srt--ProductOrServiceAxis__custom--SalesToVedcoMember_zgdg0ZkvgDt8" title="Revenue from contract with customer">198,380, respectively. This represents 70% and 67% of total revenues for the three months ended June 30, 2026 and 2025, respectively. Additional revenue of $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260401__20260630__srt--ProductOrServiceAxis__custom--ClipperMember_zIl7hMzrmOZ9" title="Revenue from contract with customer">40,520 and $<span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20250401__20250630__srt--ProductOrServiceAxis__custom--ClipperMember_zPPCAC0MRf87" title="Revenue from contract with customer">0 for the three months ended June 30, 2026 and 2025 from Clipper distributing. This represents 12% and 0% of total revenues for the three months ended June 30, 2026 and 2025, respectively. Accounts receivable from Vedco was $56,516 and $83,494 at June 30, 2026, and March 31, 2026. (M) Research and Development The Company expenses research and development costs as incurred. (N) Fair Value of Financial Instruments FASB ASC 820, Fair Value Measurements and Disclosures (“ASC 820”) establishes a framework for all fair value measurements and expands disclosures related to fair value measurement and developments. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 requires that assets and liabilities measured at fair value are classified and disclosed in one of the following three categories: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 - quoted market prices in active markets for identical assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</td></tr> </table> The carrying amounts of the Company’s financial instruments, such as cash, accounts receivable, accounts payable and other liabilities. approximates their fair value as of June 30, 2026 and March 31, 2026, due to the short-term nature of these items. The fair value of the Company’s debt approximates its carrying value as of June 30, 2026 and March 31, 2026, because the stated interest rates and terms of the debt are consistent with those currently available to the Company for similar instruments. (O) Stock-Based Compensation The Company accounts for stock-based compensation under the provisions of FASB ASC 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. In accordance with ASU No. 2018-07, Compensation – Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting share-based payment transactions for acquiring goods and services from nonemployees are included. Consistent with the accounting requirement for employee share-based payment awards, nonemployee share-based payment awards within the scope of Topic 718 are measured at grant-date fair value of the equity instruments that an entity is obligated to issue when the good has been delivered or the service has been rendered and any other conditions necessary to earn the right to benefit from the instruments have been satisfied. Stock compensation of $460,609 for the period ending June 30, 2026 consisted of; i) employee stock awards: $286,476; ii) board of directors compensation: $42,000; and iii) warrant expense: $132,133. (P) Income Tax Provision The Company is subject to income taxes in the U.S. The determination of these tax liabilities requires estimation, significant judgment, and interpretation of U.S. federal and state tax statutes, regulations, and case laws. Additionally, governing tax legislation could change significantly with little or no notice. It is important for us to monitor economic, political, and other conditions in the various countries with operations as changes in a jurisdiction’s conditions could impact the amount of deferred tax assets or our ability to utilize deferred tax assets in the future. The Company accounts for income taxes in accordance with FASB ASC 740, Income Taxes, using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the consolidated financial statement carrying amounts and the tax bases of assets and liabilities, as well as for net operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates and laws expected to apply when the related temporary differences reverse or the carryforwards are utilized. The Company establishes a valuation allowance to reduce deferred tax assets to the amount expected to be realized when, based on the available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. For the current period ending June 30, 2026 the Company has recorded a full valuation allowance against its deferred tax assets. As required by FASB ASC 740, Income Taxes, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties related to unrecognized income tax benefits in the provision for income tax expense. See Note 16. The Company is not currently under examination by any federal or state jurisdiction. (Q) Recently Issued Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. This ASU is effective for public entities with fiscal years beginning after December 15, 2024. The Company adopted this guidance for the year ended March 31, 2026 and applied the guidance on a retrospective basis. The adoption did not have a material impact on the consolidated financial statements. Refer to Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations in the Recently Issued Accounting Pronouncements section for further details. In November 2024, the FASB issued ASU 2024-03, which requires public entities to disaggregate certain expense categories in the notes to the financial statements. The standard is effective for annual periods after December 15, 2026, and interim periods after December 15, 2027, with early adoption allowed. The Company is currently evaluating the impact of this guidance on its financial statement disclosures, but does not anticipate it will affect its results of operations or cash flows. Effective January 1, 2026, the Company adopted ASU 2025-05, “Financial Instruments—Credit Losses (Topic 326): Amendments to the Measurement of Credit Losses for Short-Term Receivables.” The update provides a practical expedient that permits an entity to assume that current economic conditions as of the balance sheet date remain unchanged over the remaining life of the asset, thereby removing the requirement to incorporate future macroeconomic forecasts for qualifying short-term accounts receivable and contract assets arising from revenue transactions. The Company elected to apply the practical expedient prospectively to all current accounts receivable and contract assets within the scope of the guidance. The adoption of ASU 2025-05 did not have a material impact on our Condensed Consolidated Financial Statements and related footnote disclosures. (R) Revision of Previously Issued Financial Statements The Company identified an error in its accounting for the June 30, 2025 amendment of certain convertible notes. The Company previously recognized a beneficial conversion feature as a debt discount with a corresponding increase to additional paid-in capital. ASU 2020-06 eliminated the separate beneficial conversion feature recognition model, and the guidance was effective for the Company before the amendment. Accordingly, the Company corrected the error by removing the beneficial conversion feature and the related amortization of the debt discount. For the year ended March 31, 2026, the correction eliminated $786,908 previously recorded as a beneficial conversion feature including $23,649 related to warrants issued with promissory notes. As a result, additional paid-in capital was reduced by a net $763,259, from $103,584,614 to $102,821,355, and accumulated deficit was reduced by $763,259, from $102,075,765 to $101,312,506. The correction had no effect on cash, total assets, total liabilities, total stockholders’ equity, or net cash used in operating activities as of and for the year ended March 31, 2026. The March 31, 2026 amounts presented in these interim financial statements have been revised. For the three months ended June 30, 2025, the correction eliminated $763,259 previously presented as a beneficial conversion feature within additional paid-in capital, reducing additional paid-in capital from $97,236,660 to $96,473,401 and increasing convertible notes payable and accrued interest, net of discount from $1,129,222 to $1,892,481. Because the feature was recognized on June 30, 2025 and no related amortization was recorded during that quarter, the correction did not affect the previously reported net loss, loss per share, accumulated deficit, or net cash used in operating activities for the three months ended June 30, 2025. Total stockholders’ equity was reduced by $763,259. The following tables summarizes the effect of the errors on the Company’s audited consolidated balance sheet as of March 31, 2026 and unaudited consolidated balance sheet as of June 30, 2025: SCHEDULE OF UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zx5LUQOLRAg9" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026 As Previously Reported</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20260331__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zJTh2IAbK4Tg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260331_zhnT02gTPsdb" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026 As Revised</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40E_ecustom--CorrectionofErrorinPreviouslyIssuedAdditionalPaidInCapital_iI_z2ucjJkElg72" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Audited consolidated balance sheets - Additional Paid-In Capital</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">103,584,614</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(763,259</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">102,821,355</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--CorrectionofErrorinPreviouslyIssuedBeneficialInterest_iI_zaon9strjNvh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Audited consolidated statements of changes in stockholders’ equity - Beneficial conversion feature</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">786,908</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(786,908</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--CorrectionofErrorinPreviouslyIssuedWarrantsAndRightsOutstanding_iI_zwfhdiEfmYga" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Audited consolidated statements of changes in stockholders’ equity - Warrants issued with promissory notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,649</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,649</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--CorrectionofErrorinPreviouslyIssuedRetainedEarningsAccumulatedDeficit_iNI_di_zr843l6TG9Md" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Audited consolidated balance sheets - Accumulated Deficit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(102,075,765</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">763,259</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(101,312,506</td><td style="text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zOjFne27WxAk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"> June 30, 2025 As Previously Reported</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20250630__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zz2WZhWsOc1" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Adjustments</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20250630_zC9jCRjf9bMe" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"> June 30, 2025 As Revised</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr id="xdx_40E_ecustom--CorrectionofErrorinPreviouslyIssuedAdditionalPaidInCapital_iNI_di_zdN105zSbu16" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt; text-align: left">Unaudited condensed consolidated balance sheets - Additional Paid-In Capital</td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">97,236,660</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">(763,259</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">96,473,401</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--CorrectionofErrorinPreviouslyIssuedBeneficialInterest_iI_zrgNSg5984ba" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Unaudited condensed consolidated statements of changes in stockholders’ equity - Beneficial conversion feature</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">763,259</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(763,259</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--CorrectionofErrorinPreviouslyIssuedRetainedEarningsAccumulatedDeficit_iI_zMem3ggUuEqb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Unaudited condensed consolidated balance sheets – Convertible notes payable and accrued interest, net of discount</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">1,129,222</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">763,259</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">1,892,481</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--CorrectionofErrorinPreviouslyIssuedStockholdersEquity_iI_zH1J0oVCC5Mk" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Unaudited condensed consolidated balance sheets - Total Stockholder’s Equity</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">3,730,977</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(763,259</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">2,967,718</td><td style="font-size: 10pt; text-align: left"> </td></tr> </table> While the adjustments changed additional paid-in capital and accumulated deficit line items in the unaudited condensed consolidated balance sheets, they did not have an impact on total net cash used in operating activities, net cash used in investing activities, or net cash provided by financing activities. The related notes to the unaudited condensed consolidated financial statements have also been revised to reflect the error corrections described above. (S) Warrants The Company evaluates warrants to purchase shares of its common stock to determine the appropriate accounting and classification based on the terms of each instrument and the applicable accounting guidance. Warrants issued in share-based payment transactions for goods or services are accounted for in accordance with ASC 718, Compensation—Stock Compensation. Other freestanding warrants are evaluated under ASC 480, Distinguishing Liabilities from Equity, and ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, as applicable. Warrants that meet the criteria for equity classification are initially measured at fair value and recorded in additional paid-in capital and are not subsequently remeasured, except as otherwise required by applicable accounting guidance. Warrants that do not meet the criteria for equity classification are recorded as liabilities at fair value and are subsequently remeasured at fair value at each reporting date, with changes in fair value recognized in earnings until the warrants are exercised, expire, or otherwise no longer require liability classification.

(A) Organization and Description PetVivo Holdings, Inc. was incorporated in Nevada under its former name in 2009 and entered its current business in 2014 through a stock exchange reverse merger with PetVivo, Inc., a Minnesota corporation. This merger resulted in PetVivo, Inc. becoming a wholly owned subsidiary of PetVivo Holdings, Inc. In April 2017, PetVivo Holdings, Inc. acquired another Minnesota corporation, Gel-Del Technologies, Inc., through a statutory merger, which is also a wholly-owned subsidiary of PetVivo Holdings, Inc. In April 2025, PetVivo Holdings, Inc. changed the name of its wholly-owned subsidiary PetVivo, Inc. to PetVivo Animal Health, Inc. to better reflect the industry in which PetVivo Holdings, Inc. sells its products. The Company is in the business of licensing and commercializing our proprietary medical devices and biomaterials for the treatment and/or management of afflictions and diseases in animals, initially for dogs and horses. The Company began commercialization of its lead product Spryng® with OsteoCushion® Technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses in September 2021. The Company has a pipeline of additional products for the treatment of animals in various stages of development. The Company currently has six (6) U.S. and four (4) foreign patents issued, with two (2) additional patent applications pending with the United States Patent and Trademark Office. The patents protect the Company’s biomaterials, products, production processes and methods of use. In February 2025, The Company signed an exclusive licensing agreement with VetStem, Inc. to market and sell their PrecisePRP™ (Platelet-Rich Plasma) product for both canine and equine. On July 24, 2026, the Company terminated the licensing agreement with VetStem, Inc. The Company’s operations are conducted from its headquarter facilities in suburban Minneapolis, Minnesota with an outsourced distribution location in St. Joseph, Missouri.

(B) Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (US GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X and ASC 270-10-50. Accordingly, they do not include all of the information and footnotes required by US GAAP for complete annual financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the interim periods presented are not necessarily indicative of the results that may be expected for the full fiscal year. These interim condensed financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the company’s annual report on Form 10-K for the fiscal year ended March 31, 2026. Certain prior-period amounts have been reclassified to conform to the current-period presentation. These reclassifications had no effect on previously reported net income, total assets, total liabilities, or stockholders’ equity.

(C) Principles of Consolidation The accompanying consolidated financial statements include all the accounts of PetVivo Holdings, Inc., and its four wholly owned corporations, Gel-Del Technologies, Inc., PetVivo Animal Health, Inc., Cosmeta Corp and PetVivo AI (collectively, the “Company”). All intercompany transactions have been eliminated upon consolidation. The Company is an emerging growth company as the term is used in The Jumpstart Our Business Startups Act, enacted on April 5, 2012 and has elected to comply with certain reduced public company reporting requirements.

(D) Use of Estimates In preparation of the consolidated financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include allowance for credit losses, inventory obsolescence, estimated useful lives and potential impairment of property and equipment and intangibles, estimate of fair value of share-based payments, distributor rebate payable, provision for product returns, right of use lease assets and liabilities and valuation of deferred tax assets.

(E) Cash and Cash Equivalents The Company considers all highly-liquid, temporary cash investments with original maturity of three months or less to be cash equivalents. The Company had no cash equivalents at June 30, 2026.

(F) Concentration Risk The Company maintains its cash with various financial institutions, which at times may exceed federally insured limits. At June 30, 2026, the Company did not have cash balances in excess of the federally insured limits.

(G) Accounts Receivable Accounts receivable is carried at its contractual amounts, less an estimated allowance for credit losses. Management estimates the credit losses using a loss-rate approach based on historical loss information, adjusted for management’s expectations about current and future economic conditions, as the basis to determine expected credit losses. Management exercises significant judgment in determining expected credit losses. Key inputs include macroeconomic factors, industry trends, the creditworthiness of counterparties, historical experience, the financial conditions of the customers, and the amount and age of past due accounts. Management believes that the composition of receivables is consistent with historical conditions as credit terms and practices and the client base has not changed significantly. Receivables are considered past due if full payment is not received by the contractual due date. Past due accounts are generally written off against the allowance for credit losses only after all collection attempts have been exhausted. As of June 30, 2026 and March 31, 2026, the Company had not recorded an allowance for credit losses, as management determined that no allowance was necessary based on its assessment of the collectability of outstanding balances and the credit quality of its customers.

(H) Inventory Inventory is stated at the lower of cost and net realizable value. Cost is determined using the first-in, first-out (FIFO) method. Inventory consists of raw materials, work-in-process and finished goods. The Company evaluates inventory for excess, and obsolescence based on factors such as current inventory levels, estimated product life cycles, historical and forecasted customer demand, and input from the product development team. When necessary, an inventory write-off is recorded to reduce the carrying value of inventory to its estimated net realizable value. These estimates and assumptions are reviewed quarterly and annually and updated as needed based on the Company’s business plans and market conditions. The Company recorded an inventory write-off of $239,935 as of March 31, 2026, respectively. The inventory write-off is due to an ongoing negotiation of the VetStem licensing agreement whereby the PrecisePRP product has not been selling as originally expected. Therefore, management decided to sell the PrecisePRP product line at a discount, as to reduce the inventory levels, resulting in the Company recording an inventory write-off of $239,935.

239935

(I) Property & Equipment Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized. Maintenance and repairs are charged to operations as incurred. Depreciation is computed by the straight-line method (after considering their respective estimated residual values) over the assets estimated useful life of <span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionAndComputerEquipmentAndFurnitureMember__srt--RangeAxis__srt--MinimumMember_zo5QNd9RPIp3">3 to <span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20260630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ProductionAndComputerEquipmentAndFurnitureMember__srt--RangeAxis__srt--MaximumMember_zObm7NHvIP16" title="Estimated useful life">5 years for production and computer equipment and furniture. Leasehold improvements are depreciated using the straight-line method over the shorter of the estimated useful lives of the improvements or the remaining lease term (including renewal periods that are reasonably certain to be exercised).

P3Y

P5Y

(J) Patents and Trademarks The Company capitalizes direct costs for the maintenance and advancement of their patents and trademarks and amortizes these costs over the lesser of the useful life of <span id="xdx_90B_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtM_c20260630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsAndTrademarksMember_zcs3zYB2u8h5" title="Estimated useful life of intangible assets">60 months or the legal life of the patent. The Company evaluates the recoverability of intangible assets periodically by considering events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired. The Company has chosen to amortize over a sixty (60) month period, as the patent assets are expected to generate economic benefits for only five (<span id="xdx_907_eus-gaap--FiniteLivedIntangibleAssetUsefulLife_iI_dtY_c20260630__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--EconomicBenefitsMember_zw1sFJ0ok4Sh" title="Estimated useful life of intangible assets">5) years.

P60M

P5Y

(K) Loss Per Share The Company calculates earnings (loss) per share (“EPS”) in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 260, Earnings Per Share. Basic EPS is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock. For the years ended June 30, 2026 and 2025, the Company reported a net loss; therefore, diluted EPS is calculated the same as basic EPS, as the inclusion of all potentially dilutive securities would be anti-dilutive. The following securities were excluded from the calculation of diluted loss per share because their effect would have been anti-dilutive: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Options and warrants: 16,110,035 shares (2026); 14,668,813 shares (2025)</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Unvested RSUs: <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zRVgLAZ85W7l" title="Unvested restricted stock units">0 shares (2026); <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20250630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1uqU5RYdQC5" title="Unvested restricted stock units">205,314 shares (2025)</td></tr> </table>

16110035

14668813

205314

(L) Revenue Recognition The Company recognizes revenue in accordance with FASB ASC 606 “Revenue from Contracts with Customers.” The Company derives revenue from the sale of its pet care products directly to its veterinarian customers in the United States. The Company recognizes revenue when performance obligations under the terms of a contract with the veterinarian customer are satisfied. Product sales occur once control or title is transferred based on the commercial terms. Revenue is recognized upon delivery to the customer, which is when control of these products is transferred and in an amount that reflects the consideration the Company expects to receive for these products. Shipping costs charged to customers are reported as an offset to the respective shipping costs. The Company does not have any significant financing components as payment is received at or shortly after the point of sale. The Company entered into a Distribution Services Agreement (the “Agreement”) with MWI Veterinary Supply Co. (the “Distributor”) on June 17, 2022. Contracts with the Distributor are evidenced by individual executed purchase orders subject to the terms of the Agreement. The contracts consist of a single performance obligation related to the sale of our pet care products. Product sales occur once control or title is transferred based on the commercial terms in the Agreement. Revenue is recognized upon delivery to the Distributor; payment is due within 60 days. The Agreement provides for a distribution fee payable to the Distributor equal to 5% of gross monthly sales payable in 45 days; the distribution fee is netted against revenue. The Agreement provides for a rebate payable to the Distributor based on annual sales volume that is retroactively applied. The rebate is estimated under the expected value method and is netted against revenue. Sales are subject to various right of return provisions; the Company uses an expected value method to estimate returns and has determined that any returns would be immaterial as of June 30, 2026 and March 31, 2026. As a result, there is no return liability recorded. Shipping and handling costs are a fulfillment activity and are reported as cost of sales. In March 2025, the Company mutually terminated its non-exclusive distribution agreement with MWI. Therefore, we have no distribution fees, no rebates and no right of return provisions. As a result, the Company no longer has any distribution fees, rebates or return liabilities recorded during the three months period ending June 30, 2026 and 2025. The balance sheet continues to show a $57,264 rebate liabilities for periods from 2023-2024. Further, there were no new rebate liabilities in the quarter ending June 30, 2026. Assets and liabilities (included in accrued expenses) under the Agreement were as follows: SCHEDULE OF RECOGNIZED REVENUE ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260630_z0R1p7gpuWx5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20260331_zgIoBP0OpJa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--ReceivablesNetCurrent_iI_zHtGfjqugp0l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Accounts receivable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--RebateLiability_iI_z5nr0teFctJi" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Rebate liability</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">57,264</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">57,264</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--DistributionFeePayable_iI_zuTVzRojBAk8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Distribution fee payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,299</td><td style="text-align: left"> </td></tr> </table> We currently don’t have any distributor agreements in place, as of June 30, 2026. Product sales for all domestic shipments into the United States occur once control or title is transferred based on the commercial terms purchase orders. Revenue is recognized upon delivery to the Distributor in the United States, with international shipments, freight terms are FOB our warehouses, as ownership transfers for these international shipments when our product is picked up; payment is due within 30 days for domestic orders and payment-in-advance for international distributors. From time-to-time, we honor returns for short-dated inventory (close to expiration). Inasmuch, sales periodically are subject to returns; the Company uses an expected value method to estimate returns and has determined that any returns would be immaterial as of June 30, 2026 and March 31, 2026. As a result, there is no return liability recorded. Shipping and handling costs are a fulfillment activity and are reported as cost of sales. In December 2024, the Company entered into new wholesale distribution partnerships with Vedco, Inc. (“Vedco”) and Clipper Distributing, LLC (“Clipper”). A distribution service agreement was not signed with either distribution partner. Contracts with both distribution partners are evidenced by individual executed purchase orders. The purchase orders consist of a single performance obligation related to the sale of our pet care products. Product sales occur once control or title is transferred based on the terms in the purchase order. Revenue is recognized upon delivery to the Distributor for domestic shipments, and for international shipments, ownership transfers at the point of freight pickup from our warehouse, at which time we recognize the revenue for these international customers; payment is due within 30 days. Neither distribution partnership provides for a distribution fee payable or a rebate payable. For the three months ended June 30, 2026 and 2025, the Company recognized revenue from product sales to Vedco of $<span id="xdx_907_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260401__20260630__srt--ProductOrServiceAxis__custom--SalesToVedcoMember_zgAVhKTfgGA9" title="Revenue from contract with customer">234,623 and $<span id="xdx_908_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20250401__20250630__srt--ProductOrServiceAxis__custom--SalesToVedcoMember_zgdg0ZkvgDt8" title="Revenue from contract with customer">198,380, respectively. This represents 70% and 67% of total revenues for the three months ended June 30, 2026 and 2025, respectively. Additional revenue of $<span id="xdx_90A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20260401__20260630__srt--ProductOrServiceAxis__custom--ClipperMember_zIl7hMzrmOZ9" title="Revenue from contract with customer">40,520 and $<span id="xdx_909_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20250401__20250630__srt--ProductOrServiceAxis__custom--ClipperMember_zPPCAC0MRf87" title="Revenue from contract with customer">0 for the three months ended June 30, 2026 and 2025 from Clipper distributing. This represents 12% and 0% of total revenues for the three months ended June 30, 2026 and 2025, respectively. Accounts receivable from Vedco was $56,516 and $83,494 at June 30, 2026, and March 31, 2026.

57264 Assets and liabilities (included in accrued expenses) under the Agreement were as follows: SCHEDULE OF RECOGNIZED REVENUE ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20260630_z0R1p7gpuWx5" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20260331_zgIoBP0OpJa" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--ReceivablesNetCurrent_iI_zHtGfjqugp0l" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Accounts receivable</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--RebateLiability_iI_z5nr0teFctJi" style="vertical-align: bottom; background-color: White"> <td style="width: 60%; text-align: justify">Rebate liability</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">57,264</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">57,264</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--DistributionFeePayable_iI_zuTVzRojBAk8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Distribution fee payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,299</td><td style="text-align: left"> </td></tr> </table> 57264 57264 2299

234623

198380

0.70 0.67

40520

0.12 0

56516

83494

(M) Research and Development The Company expenses research and development costs as incurred.

(N) Fair Value of Financial Instruments FASB ASC 820, Fair Value Measurements and Disclosures (“ASC 820”) establishes a framework for all fair value measurements and expands disclosures related to fair value measurement and developments. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC 820 requires that assets and liabilities measured at fair value are classified and disclosed in one of the following three categories: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 1 - quoted market prices in active markets for identical assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</td></tr> </table> The carrying amounts of the Company’s financial instruments, such as cash, accounts receivable, accounts payable and other liabilities. approximates their fair value as of June 30, 2026 and March 31, 2026, due to the short-term nature of these items. The fair value of the Company’s debt approximates its carrying value as of June 30, 2026 and March 31, 2026, because the stated interest rates and terms of the debt are consistent with those currently available to the Company for similar instruments.

(O) Stock-Based Compensation The Company accounts for stock-based compensation under the provisions of FASB ASC 718, Compensation—Stock Compensation, which requires the measurement and recognition of compensation expense for all stock-based awards made to employees and directors based on estimated fair values on the grant date. The Company estimates the fair value of stock-based awards on the date of grant using the Black-Scholes model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods using the straight-line method. In accordance with ASU No. 2018-07, Compensation – Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting share-based payment transactions for acquiring goods and services from nonemployees are included. Consistent with the accounting requirement for employee share-based payment awards, nonemployee share-based payment awards within the scope of Topic 718 are measured at grant-date fair value of the equity instruments that an entity is obligated to issue when the good has been delivered or the service has been rendered and any other conditions necessary to earn the right to benefit from the instruments have been satisfied. Stock compensation of $460,609 for the period ending June 30, 2026 consisted of; i) employee stock awards: $286,476; ii) board of directors compensation: $42,000; and iii) warrant expense: $132,133.

460609

286476

42000 132133

(P) Income Tax Provision The Company is subject to income taxes in the U.S. The determination of these tax liabilities requires estimation, significant judgment, and interpretation of U.S. federal and state tax statutes, regulations, and case laws. Additionally, governing tax legislation could change significantly with little or no notice. It is important for us to monitor economic, political, and other conditions in the various countries with operations as changes in a jurisdiction’s conditions could impact the amount of deferred tax assets or our ability to utilize deferred tax assets in the future. The Company accounts for income taxes in accordance with FASB ASC 740, Income Taxes, using the asset and liability method. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the consolidated financial statement carrying amounts and the tax bases of assets and liabilities, as well as for net operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates and laws expected to apply when the related temporary differences reverse or the carryforwards are utilized. The Company establishes a valuation allowance to reduce deferred tax assets to the amount expected to be realized when, based on the available evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. For the current period ending June 30, 2026 the Company has recorded a full valuation allowance against its deferred tax assets. As required by FASB ASC 740, Income Taxes, the Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest and penalties related to unrecognized income tax benefits in the provision for income tax expense. See Note 16. The Company is not currently under examination by any federal or state jurisdiction.

(Q) Recently Issued Accounting Pronouncements In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. This ASU is effective for public entities with fiscal years beginning after December 15, 2024. The Company adopted this guidance for the year ended March 31, 2026 and applied the guidance on a retrospective basis. The adoption did not have a material impact on the consolidated financial statements. Refer to Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations in the Recently Issued Accounting Pronouncements section for further details. In November 2024, the FASB issued ASU 2024-03, which requires public entities to disaggregate certain expense categories in the notes to the financial statements. The standard is effective for annual periods after December 15, 2026, and interim periods after December 15, 2027, with early adoption allowed. The Company is currently evaluating the impact of this guidance on its financial statement disclosures, but does not anticipate it will affect its results of operations or cash flows. Effective January 1, 2026, the Company adopted ASU 2025-05, “Financial Instruments—Credit Losses (Topic 326): Amendments to the Measurement of Credit Losses for Short-Term Receivables.” The update provides a practical expedient that permits an entity to assume that current economic conditions as of the balance sheet date remain unchanged over the remaining life of the asset, thereby removing the requirement to incorporate future macroeconomic forecasts for qualifying short-term accounts receivable and contract assets arising from revenue transactions. The Company elected to apply the practical expedient prospectively to all current accounts receivable and contract assets within the scope of the guidance. The adoption of ASU 2025-05 did not have a material impact on our Condensed Consolidated Financial Statements and related footnote disclosures.

(R) Revision of Previously Issued Financial Statements The Company identified an error in its accounting for the June 30, 2025 amendment of certain convertible notes. The Company previously recognized a beneficial conversion feature as a debt discount with a corresponding increase to additional paid-in capital. ASU 2020-06 eliminated the separate beneficial conversion feature recognition model, and the guidance was effective for the Company before the amendment. Accordingly, the Company corrected the error by removing the beneficial conversion feature and the related amortization of the debt discount. For the year ended March 31, 2026, the correction eliminated $786,908 previously recorded as a beneficial conversion feature including $23,649 related to warrants issued with promissory notes. As a result, additional paid-in capital was reduced by a net $763,259, from $103,584,614 to $102,821,355, and accumulated deficit was reduced by $763,259, from $102,075,765 to $101,312,506. The correction had no effect on cash, total assets, total liabilities, total stockholders’ equity, or net cash used in operating activities as of and for the year ended March 31, 2026. The March 31, 2026 amounts presented in these interim financial statements have been revised. For the three months ended June 30, 2025, the correction eliminated $763,259 previously presented as a beneficial conversion feature within additional paid-in capital, reducing additional paid-in capital from $97,236,660 to $96,473,401 and increasing convertible notes payable and accrued interest, net of discount from $1,129,222 to $1,892,481. Because the feature was recognized on June 30, 2025 and no related amortization was recorded during that quarter, the correction did not affect the previously reported net loss, loss per share, accumulated deficit, or net cash used in operating activities for the three months ended June 30, 2025. Total stockholders’ equity was reduced by $763,259. The following tables summarizes the effect of the errors on the Company’s audited consolidated balance sheet as of March 31, 2026 and unaudited consolidated balance sheet as of June 30, 2025: SCHEDULE OF UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zx5LUQOLRAg9" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026 As Previously Reported</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20260331__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zJTh2IAbK4Tg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260331_zhnT02gTPsdb" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026 As Revised</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40E_ecustom--CorrectionofErrorinPreviouslyIssuedAdditionalPaidInCapital_iI_z2ucjJkElg72" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Audited consolidated balance sheets - Additional Paid-In Capital</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">103,584,614</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(763,259</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">102,821,355</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--CorrectionofErrorinPreviouslyIssuedBeneficialInterest_iI_zaon9strjNvh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Audited consolidated statements of changes in stockholders’ equity - Beneficial conversion feature</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">786,908</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(786,908</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--CorrectionofErrorinPreviouslyIssuedWarrantsAndRightsOutstanding_iI_zwfhdiEfmYga" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Audited consolidated statements of changes in stockholders’ equity - Warrants issued with promissory notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,649</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,649</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--CorrectionofErrorinPreviouslyIssuedRetainedEarningsAccumulatedDeficit_iNI_di_zr843l6TG9Md" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Audited consolidated balance sheets - Accumulated Deficit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(102,075,765</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">763,259</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(101,312,506</td><td style="text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zOjFne27WxAk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"> June 30, 2025 As Previously Reported</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20250630__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zz2WZhWsOc1" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Adjustments</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20250630_zC9jCRjf9bMe" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"> June 30, 2025 As Revised</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr id="xdx_40E_ecustom--CorrectionofErrorinPreviouslyIssuedAdditionalPaidInCapital_iNI_di_zdN105zSbu16" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt; text-align: left">Unaudited condensed consolidated balance sheets - Additional Paid-In Capital</td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">97,236,660</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">(763,259</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">96,473,401</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--CorrectionofErrorinPreviouslyIssuedBeneficialInterest_iI_zrgNSg5984ba" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Unaudited condensed consolidated statements of changes in stockholders’ equity - Beneficial conversion feature</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">763,259</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(763,259</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--CorrectionofErrorinPreviouslyIssuedRetainedEarningsAccumulatedDeficit_iI_zMem3ggUuEqb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Unaudited condensed consolidated balance sheets – Convertible notes payable and accrued interest, net of discount</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">1,129,222</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">763,259</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">1,892,481</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--CorrectionofErrorinPreviouslyIssuedStockholdersEquity_iI_zH1J0oVCC5Mk" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Unaudited condensed consolidated balance sheets - Total Stockholder’s Equity</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">3,730,977</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(763,259</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">2,967,718</td><td style="font-size: 10pt; text-align: left"> </td></tr> </table> While the adjustments changed additional paid-in capital and accumulated deficit line items in the unaudited condensed consolidated balance sheets, they did not have an impact on total net cash used in operating activities, net cash used in investing activities, or net cash provided by financing activities. The related notes to the unaudited condensed consolidated financial statements have also been revised to reflect the error corrections described above. 786908

23649

-763259

103584614

102821355

-763259

102075765

-101312506

763259

97236660

96473401

1129222

1892481

763259

The following tables summarizes the effect of the errors on the Company’s audited consolidated balance sheet as of March 31, 2026 and unaudited consolidated balance sheet as of June 30, 2025: SCHEDULE OF UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260331__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zx5LUQOLRAg9" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026 As Previously Reported</td><td style="padding-bottom: 1pt"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20260331__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zJTh2IAbK4Tg" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Adjustment</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260331_zhnT02gTPsdb" style="border-bottom: Black 1pt solid; text-align: center">March 31, 2026 As Revised</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_40E_ecustom--CorrectionofErrorinPreviouslyIssuedAdditionalPaidInCapital_iI_z2ucjJkElg72" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left">Audited consolidated balance sheets - Additional Paid-In Capital</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">103,584,614</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">(763,259</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">102,821,355</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--CorrectionofErrorinPreviouslyIssuedBeneficialInterest_iI_zaon9strjNvh" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Audited consolidated statements of changes in stockholders’ equity - Beneficial conversion feature</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">786,908</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(786,908</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--CorrectionofErrorinPreviouslyIssuedWarrantsAndRightsOutstanding_iI_zwfhdiEfmYga" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Audited consolidated statements of changes in stockholders’ equity - Warrants issued with promissory notes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,649</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,649</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_ecustom--CorrectionofErrorinPreviouslyIssuedRetainedEarningsAccumulatedDeficit_iNI_di_zr843l6TG9Md" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Audited consolidated balance sheets - Accumulated Deficit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(102,075,765</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">763,259</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(101,312,506</td><td style="text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20250630__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zOjFne27WxAk" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"> June 30, 2025 As Previously Reported</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td><td style="font-size: 10pt; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20250630__srt--RestatementAxis__srt--RevisionOfPriorPeriodReclassificationAdjustmentMember_zz2WZhWsOc1" style="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Adjustments</td><td style="padding-bottom: 1pt; font-size: 10pt; font-weight: bold"> </td><td style="font-size: 10pt; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20250630_zC9jCRjf9bMe" style="border-bottom: Black 1pt solid; font-size: 10pt; text-align: center"> June 30, 2025 As Revised</td><td style="padding-bottom: 1pt; font-size: 10pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td><td> </td> <td colspan="2" style="text-align: justify"> </td><td> </td></tr> <tr id="xdx_40E_ecustom--CorrectionofErrorinPreviouslyIssuedAdditionalPaidInCapital_iNI_di_zdN105zSbu16" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; font-size: 10pt; text-align: left">Unaudited condensed consolidated balance sheets - Additional Paid-In Capital</td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">97,236,660</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">(763,259</td><td style="width: 1%; font-size: 10pt; text-align: left">)</td><td style="width: 2%; font-size: 10pt"> </td> <td style="width: 1%; font-size: 10pt; text-align: left">$</td><td style="width: 12%; font-size: 10pt; text-align: right">96,473,401</td><td style="width: 1%; font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_406_ecustom--CorrectionofErrorinPreviouslyIssuedBeneficialInterest_iI_zrgNSg5984ba" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Unaudited condensed consolidated statements of changes in stockholders’ equity - Beneficial conversion feature</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">763,259</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(763,259</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">-</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_403_ecustom--CorrectionofErrorinPreviouslyIssuedRetainedEarningsAccumulatedDeficit_iI_zMem3ggUuEqb" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-size: 10pt; text-align: left">Unaudited condensed consolidated balance sheets – Convertible notes payable and accrued interest, net of discount</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">1,129,222</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">763,259</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">1,892,481</td><td style="font-size: 10pt; text-align: left"> </td></tr> <tr id="xdx_400_ecustom--CorrectionofErrorinPreviouslyIssuedStockholdersEquity_iI_zH1J0oVCC5Mk" style="vertical-align: bottom; background-color: White"> <td style="font-size: 10pt; text-align: left">Unaudited condensed consolidated balance sheets - Total Stockholder’s Equity</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">3,730,977</td><td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">(763,259</td><td style="font-size: 10pt; text-align: left">)</td><td style="font-size: 10pt"> </td> <td style="font-size: 10pt; text-align: left"> </td><td style="font-size: 10pt; text-align: right">2,967,718</td><td style="font-size: 10pt; text-align: left"> </td></tr> </table>

103584614 -763259 102821355 786908 -786908 23649 23649 102075765 -763259 101312506 -97236660 763259 -96473401 763259 -763259 1129222 763259 1892481 3730977 -763259 2967718 (S) Warrants The Company evaluates warrants to purchase shares of its common stock to determine the appropriate accounting and classification based on the terms of each instrument and the applicable accounting guidance. Warrants issued in share-based payment transactions for goods or services are accounted for in accordance with ASC 718, Compensation—Stock Compensation. Other freestanding warrants are evaluated under ASC 480, Distinguishing Liabilities from Equity, and ASC 815-40, Derivatives and Hedging—Contracts in Entity’s Own Equity, as applicable. Warrants that meet the criteria for equity classification are initially measured at fair value and recorded in additional paid-in capital and are not subsequently remeasured, except as otherwise required by applicable accounting guidance. Warrants that do not meet the criteria for equity classification are recorded as liabilities at fair value and are subsequently remeasured at fair value at each reporting date, with changes in fair value recognized in earnings until the warrants are exercised, expire, or otherwise no longer require liability classification.

NOTE 2 – INVENTORY Inventory consists of the following at June 30, 2026, and March 31, 2026: The inventory components are as follows: SCHEDULE OF INVENTORY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260630_zYNsnQNMLZh3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260331_zTuqKKTkTIf3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryFinishedGoods_iI_pp0p0_maINzPbd_zKkTpwWEgaw6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Finished Goods, net of allowances</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">233,144</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">291,218</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--InventoryWorkInProcess_iI_pp0p0_maINzPbd_zy6fMF3wdwIc" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Work in process</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,850</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--InventoryRawMaterials_iI_pp0p0_maINzPbd_zbzDJx46Ff9c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Raw materials</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">218,190</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">225,298</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryNet_iTI_pp0p0_mtINzPbd_zKvmgUCh0J1f" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Total Net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">451,334</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">538,366</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> As of March 31, 2026, the Company recorded an inventory write-off of $239,935 for the current market conditions with its licensed PrecisePRP™ (Platelet-Rich Plasma) product. The Company is undergoing negotiations to terminate its current licensing agreement with VetStem, whereby the PrecisePRP product has not been selling as originally expected. Therefore, management decided to sell the PrecisePRP product line at a discount, as to reduce the inventory levels, resulting in the Company recording an inventory write-off of $239,935.

The inventory components are as follows: SCHEDULE OF INVENTORY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260630_zYNsnQNMLZh3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260331_zTuqKKTkTIf3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--InventoryFinishedGoods_iI_pp0p0_maINzPbd_zKkTpwWEgaw6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Finished Goods, net of allowances</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">233,144</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">291,218</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--InventoryWorkInProcess_iI_pp0p0_maINzPbd_zy6fMF3wdwIc" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Work in process</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,850</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--InventoryRawMaterials_iI_pp0p0_maINzPbd_zbzDJx46Ff9c" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Raw materials</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">218,190</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">225,298</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryNet_iTI_pp0p0_mtINzPbd_zKvmgUCh0J1f" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Total Net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">451,334</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">538,366</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

233144

291218

21850

218190

225298

451334

538366

239935

NOTE 3 – PREPAID EXPENSES AND OTHER CURRENT ASSETS As of June 30, 2026, the Company had $283,260 in prepaid expenses and other current assets consisting primarily of $180,000 in investor relations, $25,000 in insurance costs, $41,000 in software subscription fees, $29,000 in Nasdaq and FINRA fees, and $6,000 in trade shows. As of March 31, 2026, the Company had $269,930 in prepaid expenses and other current assets consisting primarily of $102,000 in insurance costs, $72,000 in prepaid investor relations expenses, $47,000 in software subscription fees, $36,000 in OTC markets and FINRA fees, and $9,000 in consulting fees

283260

180000

25000

41000

29000

6000

269930

102000

72000 47000

36000

9000

NOTE 4 – PROPERTY AND EQUIPMENT Property and equipment consists of the following at June 30, 2026, and March 31, 2026: SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20260630_zt2y0gU1VrL6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260331_zXN89MX7SJ08" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z4gkJAPnIkZj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Leasehold improvements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">258,099</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">258,099</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zbRQWzhoPmzj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Production equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">619,229</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">619,229</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchAndDevelopmentEquipmentMember_zx8cUrkWKhTi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">R&D equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,184</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,184</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndFurnitureMember_zeQPCC6sVi93" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Computer equipment and furniture</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">167,676</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">155,306</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_maCzA3g_zTuah20i3ck5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Total, at cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,070,188</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,057,818</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msCzA3g_zidtad1Iv808" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(623,099</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(608,937</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtCzA3g_zCI6cARB4KJf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Total Net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">447,089</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">448,881</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> During the three months ended June 30, 2026, and June 30, 2025, depreciation expense was $14,162 and $16,659, respectively.

Property and equipment consists of the following at June 30, 2026, and March 31, 2026: SCHEDULE OF PROPERTY AND EQUIPMENT <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20260630_zt2y0gU1VrL6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260331_zXN89MX7SJ08" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_z4gkJAPnIkZj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Leasehold improvements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">258,099</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">258,099</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--EquipmentMember_zbRQWzhoPmzj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Production equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">619,229</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">619,229</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ResearchAndDevelopmentEquipmentMember_zx8cUrkWKhTi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">R&D equipment</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,184</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,184</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_hus-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerEquipmentAndFurnitureMember_zeQPCC6sVi93" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Computer equipment and furniture</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">167,676</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">155,306</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--PropertyPlantAndEquipmentGross_iI_maCzA3g_zTuah20i3ck5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Total, at cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,070,188</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,057,818</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msCzA3g_zidtad1Iv808" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Accumulated depreciation</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(623,099</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(608,937</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtCzA3g_zCI6cARB4KJf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Total Net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">447,089</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">448,881</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

258099

619229

25184

167676

155306

1070188

1057818

623099

608937

447089

448881

14162

16659

NOTE 5 – PATENTS AND TRADEMARKS The components of patents and trademarks, all of which are finite lived, were as follows: SCHEDULE OF COMPONENTS OF PATENTS AND TRADEMARKS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20260630_zHESo15zogIj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20260331_zEUaUjnoFYik" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedPatentsGross_iI_maCzHfP_zdWNGqqYSB1d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,870,057</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,870,057</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedTrademarksGross_iI_maCzHfP_zaFmsWZssrw4" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Trademarks</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">26,142</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">26,142</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsGross_iTI_mtCzHfP_maCzXjI_zdVX8wwVrXw7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Total at cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,896,199</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,896,199</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msCzXjI_zddA7afocukb" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Accumulated Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,876,199</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,875,690</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtCzXjI_zqMnH1aVfPPa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Total net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">20,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">20,509</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> During the three months ended June 30, 2026, and June 30, 2025, amortization expense was $509 and $1,230, respectively. The Company currently has six (6) U.S. and four (4) foreign patents issued, with two (2) additional patent applications pending with the United States Patent and Trademark Office.

The components of patents and trademarks, all of which are finite lived, were as follows: SCHEDULE OF COMPONENTS OF PATENTS AND TRADEMARKS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20260630_zHESo15zogIj" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20260331_zEUaUjnoFYik" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedPatentsGross_iI_maCzHfP_zdWNGqqYSB1d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Patents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,870,057</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,870,057</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--FiniteLivedTrademarksGross_iI_maCzHfP_zaFmsWZssrw4" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Trademarks</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">26,142</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">26,142</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--FiniteLivedIntangibleAssetsGross_iTI_mtCzHfP_maCzXjI_zdVX8wwVrXw7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify">Total at cost</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,896,199</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,896,199</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iNI_di_msCzXjI_zddA7afocukb" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Accumulated Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,876,199</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(3,875,690</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtCzXjI_zqMnH1aVfPPa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 1pt">Total net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">20,000</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">20,509</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

3870057

26142

3896199

3876199

3875690

20000

20509

509

1230

NOTE 6 –LICENSING AGREEMENTS The components of licensing agreements, all of which are finite-lived, were as follows: SCHEDULE OF LICENSING AGREEMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20260630_zbAc4yISErEe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260331_zXbn4kRBTxue" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedLicenseAgreementsGross_iI_maLANzxeH_zT7ddKUA4kk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">License Agreements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,800,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,800,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--LicensingAgreementAccumulatedImpairment_iI_di_msLANzxeH_zN13hyMZ4X7l" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accumulated Impairment Losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,000,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,000,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_ecustom--LicensingAgreementContractPayable_iI_di_msLANzxeH_zXIHQrH5xlUk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Contract Payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(125,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(125,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_ecustom--LicensingAgreementAccumulatedAmortization_iNI_di_msLANzxeH_zkGn1ZZqNlNi" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Accumulated Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(615,111</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(495,111</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40B_ecustom--LicensingAgreementNet_iTI_mtLANzxeH_zCwMyyYEhh1f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt">Total net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,059,889</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,179,889</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> In February 2025, the Company signed an exclusive licensing agreement with VetStem, Inc. to market and sell their PrecisePRP™ (Platelet-Rich Plasma) for both canine and equine products. The exclusive licensing agreement is a 5 five-year agreement whereby the Company paid an initial licensing fee of $2,000,000, which was paid in a combination of $500,000 cash, $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20250201__20250228__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_z9aeZ6b3ab5h" title="Issuances of stock">1,000,000 in stock issuances and $<span id="xdx_908_eus-gaap--FiniteLivedContractualRightsGross_iI_c20250228__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zA1bW2pkq2A1" title="Contractual payments">500,000 in future contract payments. The Company paid $125,000 in contract payments in August 2025 and $125,000 in November 2025. Future contract payments included in accrued expenses as of June 30, 2026 and March 31, 2026 were $125,000. The licensing fee is amortized over sixty (<span id="xdx_90E_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtM_c20250228__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zhNjxdTMqKw6">60) months, the term of the agreement. The licensing agreement also has a nominal royalty fee payment between <span id="xdx_903_ecustom--RoyaltyFeePaymentPercentage_pid_dp_uPure_c20250201__20250228__srt--RangeAxis__srt--MinimumMember__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zQBwxvkMmHlk">3% to <span id="xdx_906_ecustom--RoyaltyFeePaymentPercentage_pid_dp_uPure_c20250201__20250228__srt--RangeAxis__srt--MaximumMember__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zhMHrqjbLrw1">4.5%, commencing in the seventh month of the licensing agreement. The royalty fee expense was $3,872 and $0 for the three months ending June 30, 2026, and 2025, respectively. The Company also issued 250,000 warrants, with a strike price of $1.25 per share for a term of three years. The total warrant expense is fair valued at $46,030 to be amortized over thirty-six months. The Company used the Black-Scholes option pricing model to calculate the warrant fair value, with the following assumptions: <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_do_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendPaymentMember_zKJSHokxTVWk" title="Measurement input"><span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_do_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendPaymentMember_z4LxXp0zA5nl" title="Measurement input">no dividend yield, expected volatility of <span id="xdx_902_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zUtyIOPZsYQ" title="Measurement input"><span id="xdx_903_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_ztcUZTLvtuqh" title="Measurement input">115.1%, risk free interest rate of <span id="xdx_90B_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20260630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_z3YKkJDIGDj4" title="Measurement input"><span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zDWRyvhaJk2l" title="Measurement input">4.02%, and expected warrant life of 3 years. Warrant expense was $15,348 and $0 for the three months ending June 30, 2026, and 2025, respectively. Amortization expense was $100,000 for the three months ended June 30, 2026, and 2025. As of March 31, 2026, the Company decided the long-term viability of selling the VetStem PrecisePRP products was not in the Company’s best interests, as the market is not accepting the PRP product as expected. The Company sent VetStem a Notice of Termination for the license agreement, along with a transition period to move the remaining inventory within a six-to-nine-month period. This licensing agreement Notice of Termination effectively reduces the licensing agreement from 60 months to 24 months, resulting in a licensing agreement impairment expense for the reduction of the licensing period. As of March 31, 2026, the Company recorded an impairment expense of $1,000,000. As a result of termination negotiations, the Company derecognized the $125,000 final milestone payment obligation, resulting in a corresponding reduction of the related contract payable. In September 2025, the Company signed an exclusive licensing agreement with Digital Landia Holding Corp to utilize their Artificial Intelligence (AI) under a B2B white-label model to target a bigger share of the veterinary industry within North America, the United Kingdom, and potentially other markets. The Company will market the software as its own brand and logo through exclusive Software-as-a-Service access rights. The exclusive licensing agreement is a <span id="xdx_904_ecustom--LicensingAgreementTerm_dtY_c20250901__20250930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_z9hpmtz52pa3" style="display: none" title="Licensing agreement term">10 ten-year agreement whereby the Company issued <span id="xdx_90A_ecustom--StockIssuedDuringPeriodSharesCommonStockIssuedForLicensingAgreement_c20250901__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zG3hcPbo5Q1a" title="Common stock issued for licensing agreement, shares">1,000,000 shares of its common stock, with a fair value of $<span id="xdx_901_ecustom--StockIssuedDuringPeriodValueCommonStockIssuedForLicensingAgreement_c20250901__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zrnFvgGLbrdi" title="Common stock issued for licensing agreement">800,000, for the licensing fee. The fair value of the common stock issued as consideration was determined based on the quoted market price of the Company’s common stock on the measurement date. The licensing fee is recorded as an intangible asset and is amortized over one-hundred twenty (<span id="xdx_903_eus-gaap--FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_iI_dtM_c20250930__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zXX2dcdmAXml" title="Finite lived intangible assets remaining amortization period">120) months, the term of the agreement. The licensing agreement also has a royalty fee payment between <span id="xdx_907_ecustom--RoyaltyFeePaymentPercentage_pid_dp_uPure_c20250901__20250930__srt--RangeAxis__srt--MinimumMember__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_z8oHdk6uABf5" title="Royalty fee payment percentage">10% and <span id="xdx_90F_ecustom--RoyaltyFeePaymentPercentage_pid_dp_uPure_c20250901__20250930__srt--RangeAxis__srt--MaximumMember__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--LicensingAgreementsMember_zqBb0bDztZ0e" title="Royalty fee payment percentage">15%, commencing in the thirteenth month of the licensing agreement. No royalty expense was incurred for the three months ended June 30, 2026, and 2025, respectively. Amortization expense was $20,000 and $0 for the three months ended June 30, 2026, and 2025, respectively. The components of licensing agreements, all of which are finite-lived, were as follows: SCHEDULE OF LICENSING AGREEMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20260630_zbAc4yISErEe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260331_zXbn4kRBTxue" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40D_eus-gaap--FiniteLivedLicenseAgreementsGross_iI_maLANzxeH_zT7ddKUA4kk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">License Agreements</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,800,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,800,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_409_ecustom--LicensingAgreementAccumulatedImpairment_iI_di_msLANzxeH_zN13hyMZ4X7l" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accumulated Impairment Losses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,000,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,000,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_404_ecustom--LicensingAgreementContractPayable_iI_di_msLANzxeH_zXIHQrH5xlUk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Contract Payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(125,000</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(125,000</td><td style="text-align: left">)</td></tr> <tr id="xdx_405_ecustom--LicensingAgreementAccumulatedAmortization_iNI_di_msLANzxeH_zkGn1ZZqNlNi" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Accumulated Amortization</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(615,111</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(495,111</td><td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr id="xdx_40B_ecustom--LicensingAgreementNet_iTI_mtLANzxeH_zCwMyyYEhh1f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt; padding-left: 10pt">Total net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,059,889</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">1,179,889</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

2800000

1000000 1000000 125000 125000 615111 495111 1059889 1179889 P5Y 2000000

500000

1000000

500000

125000

125000 125000

P60M

0.03 0.045

3872

250000

1.25

P3Y

46030

115.1

4.02

P3Y

15348

100000

1000000 125000 P10Y 1000000 800000

P120M

0.10 0.15

20000

NOTE 7 – ACCRUED EXPENSES The components of accrued expenses were as follows: SCHEDULE OF COMPONENTS OF ACCRUED EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260630_zjfiZK28qDp8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260331_zU16nS3TkR5l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_ecustom--ContractPayable_iI_pp0p0_maALCztTK_zRrPAFMrLwT9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Contract payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">125,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">125,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_maALCztTK_zPjrNq1PsKaj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accrued payroll and related taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,492</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">134,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--AccruedExpensesCurrent_iI_pp0p0_maALCztTK_zsFSeFZsIZD1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Accrued expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">196,419</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">194,713</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCztTK_zYKGW0YF81ec" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">344,911</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">453,713</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

The components of accrued expenses were as follows: SCHEDULE OF COMPONENTS OF ACCRUED EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260630_zjfiZK28qDp8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260331_zU16nS3TkR5l" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_409_ecustom--ContractPayable_iI_pp0p0_maALCztTK_zRrPAFMrLwT9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify">Contract payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">125,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">125,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_maALCztTK_zPjrNq1PsKaj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Accrued payroll and related taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,492</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">134,000</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_ecustom--AccruedExpensesCurrent_iI_pp0p0_maALCztTK_zsFSeFZsIZD1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Accrued expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">196,419</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">194,713</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--AccruedLiabilitiesCurrent_iTI_pp0p0_mtALCztTK_zYKGW0YF81ec" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: justify; padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">344,911</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">453,713</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

125000 125000

23492

134000

196419 194713

344911

453713

NOTE 8 – NOTES PAYABLE AND ACCRUED INTEREST In February and March 2026, the Company entered into two separate promissory notes totaling $320,000. The notes accrued interest at a rate of <span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260228__us-gaap--DebtInstrumentAxis__custom--TwoSeperatePromissoryNotesMember_z8jsAgUKGJKh" title="Debt instrument interest rate stated percentage"><span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260331__us-gaap--DebtInstrumentAxis__custom--TwoSeperatePromissoryNotesMember_zZuaFN8cUjtb" title="Debt instrument interest rate stated percentage">6% per annum. The first promissory note was initiated on February 26, 2026, in the amount of $150,000 with a maturity date of February 26, 2027. The second promissory note was initiated on March 11, 2026, in the amount of $170,000 with a maturity date of March 11, 2027. On June 22, 2026, the Company entered into a third promissory note totaling $150,000 with a maturity date of June 22, 2027, with an accrued interest rate of <span id="xdx_907_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_uPure_c20260622__us-gaap--DebtInstrumentAxis__custom--ThirdPromissoryNotesMember_zGDVj6alGuAh" title="Debt instrument interest rate stated percentage">6% per annum. Accrued interest on all notes at June 30, 2026, was $6,456. As of June 30, 2026, total non-convertible notes payable, including accrued interest, were $476,456, consisting of $476,456 classified as current liability and $0 classified as long-term liabilities. As of March 31,2026, the balance totalled $321,447, consisting of $321,447 classified as current liability and $0 classified as long-term liabilities within other liabilities. Total Interest expense for all Notes for the three months ended June 30, 2026 and 2025 is $5,039 and $121,808, respectively.

320000

0.06

150000

2027-02-26

170000

2027-03-11

150000

2027-06-22

0.06

6456

476456

321447

5039

121808

NOTE 9 – CONVERTIBLE NOTES PAYABLE AND ACCRUED INTEREST On March 8, 2024, the Company entered into a convertible promissory note for $150,000. The note accrued interest at a rate of 10% per annum. The principal and accrued interest were due in April 2024. The holder of the note had the option to convert the principal and accrued interest into shares of the Company’s common stock at a conversion rate of $0.70 per share. On April 10, 2024, the company entered into another promissory note for an additional $150,000 whereby the new principal balance was $300,000 with the same terms. On April 29, 2024, the noteholder converted the $300,000 principal balance, along with $1,558 of accrued interest into <span id="xdx_900_eus-gaap--DebtConversionConvertedInstrumentSharesIssued1_pid_c20240429__20240429__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z6sdBpSXDyxb" title="Debt conversion, converted instrument, shares issued">430,798 common shares. From September 1, 2024 through March 31, 2025, the Company borrowed $1,715,000 in convertible promissory notes with conversion terms of the lessor of our stock trading price or $0.50 per share with an interest rate of 10% per annum. On June 10, 2025, the Company entered into a promissory note for $160,000 at a rate of 10% per annum and a maturity date of December 31, 2025. This note included the issuance of 75,000 warrants, with a 2 two-year term and a strike price of $0.75 per share and had a fair value of $23,649. The Company used the Black-Scholes option pricing model to calculate the warrant fair value, with the following assumptions: <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_do_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendPaymentMember_zJHGWi7wyGll" title="Measurement input">no dividend yield, expected volatility of <span id="xdx_90F_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zB7a4gyxBUp2" title="Measurement input">119.3%, risk free interest rate of <span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_pid_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zyqCGBMnhd37" title="Measurement input">3.72%, and expected option life of 2.0 years. The fair value is required to be recorded as a debt discount and amortized to interest expense over the term of the note. Amortization of the debt discount, included in interest expense, was $2,956 and $23,649 for the three and nine months ended December 31, 2025. On September 30, 2025, the Company repaid a $25,000 convertible promissory note, dated December 20, 2024, and accrued interest of $2,334. On September 30, 2025, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_c20250930__20250930__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zfl6crGvOcI1" title="Stock issued during period shares conversion of convertible notes">3,669,806 shares of common stock, with a fair value of $2,018,154, for conversion of all of the remaining convertible notes in the amount of $1,850,000 and accrued interest of $168,154. The total convertible notes payable, including accrued interest, for these convertible notes is $0 at June 30, 2026 and March 31, 2026. Interest expense, including amortization of debt discount, on these convertible notes payable for the three months ending June 30, 2026 and 2025 is $0 and $66,259. June 30, 2025 Amendment to Convertible Notes and Extinguishment Accounting On June 30, 2025, the Company and the noteholders entered into an amendment to fix the conversion price at $0.50 per share, eliminate the variable pricing feature, and change all maturity dates to September 30, 2025. As a result of the amendment, the conversion feature no longer required separate derivative liability accounting under ASC 815. Under ASC 470-20, as amended by ASU 2020-06, the conversion feature was not separately recognized from the debt host. The Company evaluated the amendment under ASC 470-50, Modifications and Extinguishments, and concluded that the amendment represented a substantial modification due to the reclassification of the conversion feature from a liability to equity and the resulting change in economic substance. Accordingly, the Company accounted for the amendment as an extinguishment of the existing notes and the issuance of new convertible notes. The new debt instrument issued upon extinguishment was recorded at its estimated fair value of $1,215,000. In accordance with ASC 470-20, as amended by ASU 2020-06, the conversion feature was not separately recognized as a beneficial conversion feature, and no related debt discount or increase to additional paid-in capital was recorded. The accounting impact of the amendment is summarized as follows, as of June 30, 2025: SCHEDULE OF AMENDMENT TO CONVERTIBLE NOTES AND EXTINGUISHMENT ACCOUNTING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Description</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Carrying amount of extinguished debt</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ExtinguishmentOfDebtAmount_c20250630__20250630_zOO8FgznE8yl" style="width: 16%; text-align: right" title="Carrying amount of extinguished debt">1,215,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of new debt issued</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--DebtInstrumentFairValue_iI_c20250630_zYneo2jtwPOl" style="text-align: right" title="Fair value of new debt issued">1,215,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of derivative reclassified to equity</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--FairValueOfDerivativeReclassifiedToEquity_c20250630__20250630_zm3tJOUq91Xb" style="text-align: right" title="Fair value of derivative reclassified to equity">768,493</td><td style="text-align: left"> </td></tr> </table> The amended convertible notes were matured and were fully converted on September 30, 2025. Convertible Notes Issued with Warrants On February 14, 2025, a total of 250,000 warrants were issued for two Notes totaling $500,000. The warrants have a three-year term with an exercise strike price of $0.90 per share. The warrants were evaluated under ASC 480 and ASC 815 and determined to be equity-classified instruments. The fair value of the warrants at inception was recorded at a discount to the carrying value of the associated notes and is being amortized to interest expense over the term of the notes using the effective interest method. The fair value at issuance was estimated using the binomial option pricing model with the following inputs: closing stock price of $<span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20250214__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOfferedPriceMember_zkahiOcxbBQd">0.74, strike price of $<span id="xdx_907_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20250214__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z7nrqs1CoFNd">0.90, <span id="xdx_90C_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20250214__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zawB2Ydp37o2">3-year term, volatility rate of <span id="xdx_90A_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20250214__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputOptionVolatilityMember_zfWHBtEtfVza">113.7%, risk-free rate of <span id="xdx_909_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_uPure_c20250214__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zv2zqQAn1xU4">4.26%, and dividend yield of <span id="xdx_906_eus-gaap--WarrantsAndRightsOutstandingMeasurementInput_iI_dc_uPure_c20250214__us-gaap--ShortTermDebtTypeAxis__us-gaap--ConvertibleDebtMember__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_z72lmlsVf8Qj">zero. The fair value of the warrants at inception was $98,684 and were being amortized over the thirty-six month term. On September 30, 2025, the convertible notes were converted into common stock and the unamortized remaining balance of the debt discount of $90,219 was fully amortized. Interest expense related to the amortization of the debt discounts associated with warrants was $0 and $10,246 for the three months ending June 30, 2026 and 2025, respectively. Fair Value Allocation of Proceeds from Convertible Notes When convertible notes are issued with warrants, and no derivative liability is present, the proceeds are allocated between the debt and the warrants based on their relative fair values at issuance. When convertible notes are issued with both detachable warrants and embedded derivative liabilities, the proceeds are allocated using a sequential approach: first to the derivative liability at fair value, then to the warrants at fair value, and the residual amount to the debt host. For convertible notes that include only an embedded derivative liability and no warrants, the proceeds are allocated first to the derivative liability at fair value, with the residual amount allocated to the debt host. Derivative Liabilities – Variable Conversion Features The Company had $1,215,000 of convertible notes that contained derivative features and evaluated the terms of these convertible notes and determined that certain embedded conversion features were not indexed to the Company’s own stock due to variable conversion price provisions. Accordingly, the embedded conversion features were bifurcated from the host debt instruments and accounted for as derivative liabilities in accordance with ASC 815, Derivatives and Hedging. All of the convertible notes contained derivatives, with similar conversion terms. The derivative liabilities were measured at fair value on a recurring basis and classified as Level 3 within the fair value hierarchy due to the use of significant unobservable inputs. The initial fair value of the embedded derivatives was recorded as a debt discount with a corresponding derivative liability and was amortized to interest expense over the contractual term of the related notes using the effective interest method. The fair value of the derivative liabilities was estimated using a binomial option pricing model. The significant assumptions utilized in determining the fair value of the derivative liabilities, based on the weighted-average of the convertible notes, were as follows: SCHEDULE OF FAIR VALUE OF THE DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: justify">Input</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Inception</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31, 2025</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2025</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Closing stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250214__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z4pq6FjpMbjk" style="width: 16%; text-align: right" title="Derivative liability measurement input">0.41</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zBBkd8jGd5ij" style="width: 16%; text-align: right" title="Derivative liability measurement input">0.60</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zPKFm9gwSqc4" style="width: 16%; text-align: right" title="Derivative liability measurement input"> 1.10</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Conversion price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250214__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember_zCoYQ5TVApsj" style="text-align: right" title="Derivative liability measurement input">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember_zTtx3tzBAqKe" style="text-align: right" title="Derivative liability measurement input">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember_zz1EdCwuNwkj" style="text-align: right" title="Derivative liability measurement input">0.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Remaining contractual term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250214__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zV0bKkJ9h4zh" title="Derivative liability measurement input">3.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zuPmInGvoLS7" title="Derivative liability measurement input">2.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zI9R5ZiqlIbi" title="Derivative liability measurement input">2.25</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250214__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zdPeHLtfFaie" style="text-align: right" title="Derivative liability measurement input">135.1</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zrmNg0VVnvol" style="text-align: right" title="Derivative liability measurement input">103.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zxJ5Z9qw6C8d" style="text-align: right" title="Derivative liability measurement input">82.1</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250214__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zHyNQAADZXJ2" style="text-align: right" title="Derivative liability measurement input">4.16</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zVMVXYbZJs47" style="text-align: right" title="Derivative liability measurement input">4.08</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zO0iSfskZZ1b" style="text-align: right" title="Derivative liability measurement input">3.85</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250214__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zxfvV1QXtFPi" style="text-align: right" title="Derivative liability measurement input">0.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zhGZqJRFT35j" style="text-align: right" title="Derivative liability measurement input">0.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zfqvltaTiova" style="text-align: right" title="Derivative liability measurement input">0.0</td><td style="text-align: left">%</td></tr> </table> The following table summarizes activity in the Company’s derivative liabilities: SCHEDULE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Fair value at inception</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilities_iS_c20251231__20251231_zN9JORxzJFDe" style="width: 16%; text-align: right" title="Derivative liability">341,576</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Change in fair value during fiscal 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--UnrealizedGainLossOnDerivatives_c20251231__20251231_zjCVQ2coGgl1" style="text-align: right" title="Change in fair value">106,513</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Fair value at March 31, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--DerivativeLiabilities_iS_c20250401__20250630_zZkhlRTDW4x8" style="text-align: right" title="Derivative liability">448,089</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Change in fair value through June 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--UnrealizedGainLossOnDerivative_c20250401__20250630_zfL0meFjEMq8" style="text-align: right" title="Change in fair value">320,404</td><td style="text-align: left"></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Fair value at amendment in June 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--FairValueImmediatelyPriorToConversion_c20250701__20260630_zgdky9NRO3Ie" style="text-align: right" title="Fair value immediately prior to conversion">768,493</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Derivative liabilities reclassified to equity upon amendment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--DerivativeLiabilitiesExtinguishedUponConversion_c20250701__20260630_z0d76nT6xy81" style="text-align: right" title="Derivative liabilities extinguished upon conversion">(768,493</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Fair value at June 30, 2026</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_iE_c20250701__20260630_z8q0YdPvofkl" style="text-align: right" title="Derivative liability">0</td><td style="text-align: left"> </td></tr> </table> The Company recognized an unrealized loss of $320,404 related to changes in the fair value of derivative liabilities for the three months ended June 30, 2025. On September 30, 2025, all outstanding convertible notes containing embedded derivative features were converted into shares of the Company’s common stock. No gain or loss was recognized upon conversion. As a result, the Company had no outstanding derivative liabilities as of June 30, 2026 and March 31, 2026. Interest expense related to the amortization of debt discounts associated with derivative liabilities was $0 and $56,013 for the three months ending June 30, 2026 and 2025, respectively.

150000

0.10

0.70

150000

300000

1558

430798

1715000

0.50

0.10

160000

0.10

75000

P2Y

0.75

23649

119.3

3.72

P2Y

2956 23649

25000

2334

3669806

2018154

1850000

168154

66259

0.50

1215000

The accounting impact of the amendment is summarized as follows, as of June 30, 2025: SCHEDULE OF AMENDMENT TO CONVERTIBLE NOTES AND EXTINGUISHMENT ACCOUNTING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Description</td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">Carrying amount of extinguished debt</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ExtinguishmentOfDebtAmount_c20250630__20250630_zOO8FgznE8yl" style="width: 16%; text-align: right" title="Carrying amount of extinguished debt">1,215,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Fair value of new debt issued</td><td> </td> <td style="text-align: left">$</td><td id="xdx_989_eus-gaap--DebtInstrumentFairValue_iI_c20250630_zYneo2jtwPOl" style="text-align: right" title="Fair value of new debt issued">1,215,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Fair value of derivative reclassified to equity</td><td> </td> <td style="text-align: left">$</td><td id="xdx_98A_ecustom--FairValueOfDerivativeReclassifiedToEquity_c20250630__20250630_zm3tJOUq91Xb" style="text-align: right" title="Fair value of derivative reclassified to equity">768,493</td><td style="text-align: left"> </td></tr> </table>

1215000

768493

250000

500000

0.90

0.74

0.90

113.7

4.26

98684

90219

10246

1215000

The fair value of the derivative liabilities was estimated using a binomial option pricing model. The significant assumptions utilized in determining the fair value of the derivative liabilities, based on the weighted-average of the convertible notes, were as follows: SCHEDULE OF FAIR VALUE OF THE DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: justify">Input</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">Inception</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">March 31, 2025</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; white-space: nowrap; font-weight: bold; text-align: center">June 30, 2025</td><td style="white-space: nowrap; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; text-align: justify">Closing stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250214__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_z4pq6FjpMbjk" style="width: 16%; text-align: right" title="Derivative liability measurement input">0.41</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zBBkd8jGd5ij" style="width: 16%; text-align: right" title="Derivative liability measurement input">0.60</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputSharePriceMember_zPKFm9gwSqc4" style="width: 16%; text-align: right" title="Derivative liability measurement input"> 1.10</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Conversion price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_983_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250214__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember_zCoYQ5TVApsj" style="text-align: right" title="Derivative liability measurement input">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_980_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember_zTtx3tzBAqKe" style="text-align: right" title="Derivative liability measurement input">0.50</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputConversionPriceMember_zz1EdCwuNwkj" style="text-align: right" title="Derivative liability measurement input">0.50</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Remaining contractual term (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250214__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zV0bKkJ9h4zh" title="Derivative liability measurement input">3.0</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_907_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zuPmInGvoLS7" title="Derivative liability measurement input">2.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_901_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedTermMember_zI9R5ZiqlIbi" title="Derivative liability measurement input">2.25</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Expected volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250214__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zdPeHLtfFaie" style="text-align: right" title="Derivative liability measurement input">135.1</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zrmNg0VVnvol" style="text-align: right" title="Derivative liability measurement input">103.5</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputPriceVolatilityMember_zxJ5Z9qw6C8d" style="text-align: right" title="Derivative liability measurement input">82.1</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Risk-free interest rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250214__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zHyNQAADZXJ2" style="text-align: right" title="Derivative liability measurement input">4.16</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zVMVXYbZJs47" style="text-align: right" title="Derivative liability measurement input">4.08</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputRiskFreeInterestRateMember_zO0iSfskZZ1b" style="text-align: right" title="Derivative liability measurement input">3.85</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250214__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zxfvV1QXtFPi" style="text-align: right" title="Derivative liability measurement input">0.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98F_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250331__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zhGZqJRFT35j" style="text-align: right" title="Derivative liability measurement input">0.0</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--DerivativeLiabilityMeasurementInput_iI_uPure_c20250630__us-gaap--MeasurementInputTypeAxis__us-gaap--MeasurementInputExpectedDividendRateMember_zfqvltaTiova" style="text-align: right" title="Derivative liability measurement input">0.0</td><td style="text-align: left">%</td></tr> </table>

0.41

0.60

1.10

0.50

3.0

2.75

2.25

135.1

103.5

82.1

4.16

4.08

3.85

0.0

The following table summarizes activity in the Company’s derivative liabilities: SCHEDULE OF DERIVATIVE LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Amount</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Fair value at inception</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--DerivativeLiabilities_iS_c20251231__20251231_zN9JORxzJFDe" style="width: 16%; text-align: right" title="Derivative liability">341,576</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Change in fair value during fiscal 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98D_eus-gaap--UnrealizedGainLossOnDerivatives_c20251231__20251231_zjCVQ2coGgl1" style="text-align: right" title="Change in fair value">106,513</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Fair value at March 31, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--DerivativeLiabilities_iS_c20250401__20250630_zZkhlRTDW4x8" style="text-align: right" title="Derivative liability">448,089</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Change in fair value through June 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98B_ecustom--UnrealizedGainLossOnDerivative_c20250401__20250630_zfL0meFjEMq8" style="text-align: right" title="Change in fair value">320,404</td><td style="text-align: left"></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Fair value at amendment in June 30, 2025</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--FairValueImmediatelyPriorToConversion_c20250701__20260630_zgdky9NRO3Ie" style="text-align: right" title="Fair value immediately prior to conversion">768,493</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Derivative liabilities reclassified to equity upon amendment</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--DerivativeLiabilitiesExtinguishedUponConversion_c20250701__20260630_z0d76nT6xy81" style="text-align: right" title="Derivative liabilities extinguished upon conversion">(768,493</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify">Fair value at June 30, 2026</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--DerivativeLiabilities_iE_c20250701__20260630_z8q0YdPvofkl" style="text-align: right" title="Derivative liability">0</td><td style="text-align: left"> </td></tr> </table>

341576

106513

448089

320404 768493 -768493

-320404

56013

NOTE 10 – RETIREMENT PLAN In February 2021, the Company established a defined contribution retirement plan under Section 401(k) of the Internal Revenue Code for eligible employees. Participants may contribute a portion of their eligible compensation to the plan, subject to applicable statutory limitations. The Company may make discretionary employer contributions. Employer contribution expense was $18,422 and $15,879 for the three months ended June 30, 2026 and 2025, respectively.

18422

15879

NOTE 11 – COMMITMENTS AND CONTINGENCIES The Company accounts for contingencies in accordance with ASC 450, Contingencies. A liability is recorded when it is probable that a loss has been incurred and the amount can be reasonably estimated. If a loss is reasonable possible but not probable, or if the amount cannot be estimated, the nature of the contingency and an estimate of the possible loss, if determinable, is disclosed. Remote contingencies are generally not disclosed unless related to guarantee. Lease Obligations The Company leases property and equipment under operating leases, typically with terms greater than 12 months, and determine if an arrangement contains a lease at inception. In general, an arrangement contains a lease if there is an identified asset and we have the right to direct the use of and obtain substantially all of the economic benefit from the use of the identified asset. We record an operating lease liability at the present value of lease payments over the lease term on the commencement date. The related right of use (‘‘ROU”) operating lease asset reflects rental escalation clauses, as well as renewal options and/or termination options. The exercise of lease renewal and/or termination options is at our discretion and is included in the determination of the lease term and lease payment obligations when it is deemed reasonably certain that the option will be exercised. When available, we use the rate implicit in the lease to discount lease payments to present value; however, certain leases do not provide a readily determinable implicit rate. Therefore, we must estimate our incremental borrowing rate to discount the lease payments based on information available at lease commencement. The Company classifies our leases as buildings, vehicles or computer and office equipment and do not separate lease and non-lease components of contracts for any of the aforementioned classifications. In accordance with applicable guidance, we do not record leases with terms that are less than one year on the Consolidated Balance Sheets. None of our lease agreements contain material restrictive covenants or residual value guarantees. Buildings The Company entered into an 84 eighty-four month lease for 3,577 square feet of newly constructed office, laboratory, and warehouse space located in Edina, Minnesota in May 2017, which was renewed for an additional thirty months resulting in the lease expiration in November 2026. The base rent has annual increases of 2% and the Company is responsible for its proportional share of common space expenses, property taxes, and building insurance. This lease is terminable by the landlord if damage causes the property to no longer be utilized as an integrated whole and by the Company if damage causes the facility to be unusable for a period of 45 days. <span id="xdx_904_eus-gaap--LesseeOperatingLeaseOptionToExtend_c20200101__20200131__us-gaap--TypeOfArrangementAxis__custom--ExtendedLeaseTermToTwoThousandTwentySixMember_z3fYFGiY26jc" title="Lease term description">In January 2020, the Company entered into a lease amendment to extend the lease term through November of 2026 in exchange for receipt of a loan of $42,500 recorded to note payable. The monthly base rent as of June 30, 2026, and March 31, 2026, was $2,434. The Company entered into a <span id="xdx_90B_eus-gaap--LessorOperatingLeaseTermOfContract_iI_dtM_c20220131__us-gaap--TypeOfArrangementAxis__custom--JanuaryTwoThousandTwentyTwoLeaseMember_zKhfMcFHO6R4" style="display: none" title="Lessor operating lease term of contract">63 sixty-three month lease for 2,400 square feet of office space located in Edina, Minnesota in January 2022. This lease will expire in March 2027. The base rent has annual increases of <span id="xdx_90B_ecustom--PercentageOfIncreaseInRent_pid_dp_uPure_c20220101__20220131__us-gaap--TypeOfArrangementAxis__custom--JanuaryTwoThousandTwentyTwoLeaseMember_zJO15XPwfYJk" title="Annual increase in base rent, percentage">2.5% and the Company is responsible for its proportional share of common space expenses, property taxes, and building insurance. The monthly base rent as of June 30, 2026, and March 31, 2026, was $2,950. On January 10, 2023, the Company entered into a new lease agreement for approximately 14,000 square feet of production and warehouse space with a commencement date of April 1, 2023, which is when the control and right of use for this asset took place. The initial monthly base rent is $8,420 and has annual increases of <span id="xdx_902_ecustom--PercentageOfIncreaseInRent_pid_dp_uPure_c20230110__20230110__us-gaap--TypeOfArrangementAxis__custom--JanuaryTenTwoThousandTwentyThreeLeaseMember_zTCqEfuj1Doe" title="Annual increase in base rent, percentage">2.5%. The Company is also responsible for its proportional share of common space expenses, property taxes, and building insurance. <span id="xdx_909_eus-gaap--LesseeOperatingLeaseOptionToTerminate_pid_dp_uPure_c20230110__20230110__us-gaap--TypeOfArrangementAxis__custom--JanuaryTenTwoThousandTwentyThreeLeaseMember_zOaGACHGAVrc" title="Lease termination">The lease will terminate on June 30, 2033, and the Company has a renewal option for a period of five years. The monthly base rent as of June 30, 2026, and March 31, 2025 was $0. Lease Termination Effective June 30, 2025, the Company terminated its ten-year lease for approximately 14,000 square feet of production and warehouse space. In connection with the termination, the Company agreed to reimburse the landlord for certain unamortized leasing costs, rent abatements, tenant improvements, legal and management fees, costs associated with releasing a mechanical lien, and an amount equal to six months of base rent, common area maintenance charges and real estate taxes attributable to approximately <span id="xdx_90D_eus-gaap--AreaOfLand_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--TenYearLeaseAgreementMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--UnrentedOfficeAreaMember_zQ8dB3FF1kPi" title="Area of land">3,794 square feet of unrented office space. Upon termination of the lease, the Company derecognized the related operating lease right-of-use asset of $843,783 and operating lease liability of $843,783 and recognized a loss on lease termination of $149,125. The Company also incurred lease termination and related costs of $314,768 during the year ended March 31, 2026. No such costs were incurred during the year ended March 31, 2025. No additional lease termination costs were recognized during the three months ended June 30, 2026. The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of June 30, 2026: SCHEDULE OF MATURITY OF ANNUAL UNDISCOUNTED OPERATING LEASE LIABILITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20260630_zuYwFgl34nuj" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPz27w_zS7fcmF5qHAg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2027</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">38,654</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz27w_zyTXzfjY4WR2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPz27w_znFQ7c0Y9Dcj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPz27w_zZu3ekr0eaN6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2030</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pp0p0_maLOLLPz27w_z09QxqiE9qu1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz27w_zk0rxcuRwlv7" style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">38,654</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_maLOLLPzuI9_zICOmPH1nOkh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: amount representing interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iI_pp0p0_maLOLLPzuI9_zth9QDAAR4ok" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">38,654</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> In compliance with ASC 842 Leases, the Company recognized, based on the extended lease terms to November 7, 2026, and March 2027, a weighted average incremental borrowing rate of <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20260630__us-gaap--AwardDateAxis__custom--MarchTwoThousandTwentySevenMember_zKEQPic6nzy6" title="Operating lease discount rate percentage">3.20%, an operating lease right-of-use assets for approximately $38,654 and corresponding and equal operating lease liabilities for the leases. As of June 30, 2026, the present value of future base rent lease payments based on the remaining lease term of 0.6 years, are as follows: SCHEDULE OF BASE RENT LEASE PAYMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20260630_zIiCFNsLGJY8" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--OperatingLeaseLiabilityGross_iI_pp0p0_zXmr9vnCaqjj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Present value of future base rent lease payments</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">38,654</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--BaseRentPaymentsIncludedInPrepaidExpenses_iI_pp0p0_zd7FI2E9gvg3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Base rent payments included in prepaid expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--OperatingLeaseLiabilities_iI_pp0p0_zXHY9q5wMcOk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Present value of future base rent lease payments – net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">38,654</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> As of June 30, 2026 and March 31, 2026, operating lease right-of-use assets and operating lease liabilities were classified as follows: SCHEDULE OF LEASE CURRENT AND NON-CURRENT ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20260630_znKW2NpMjfJc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20260331_zUXtUVoAGxYf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_ecustom--OperatingLeaseRightofuseCurrentAsset_iI_pp0p0_zm4saLOvzHOf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify; padding-bottom: 1pt">Operating lease right-of-use asset</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">38,654</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">54,711</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_ze6NgpRdAIVj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total operating lease assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38,654</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,711</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_zCVUdBRZfhXf" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Operating lease current liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38,654</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,711</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zvSsNVnUbyti" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Operating lease non-current liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--OperatingLeaseLiabilities_iI_pp0p0_z49mXNtcZ6G3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">38,654</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">54,711</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Employment Agreements The Company has employment agreements with its executive officers. As of June 30, 2026, these agreements contain severance benefits ranging from one month to six months if terminated without cause. Legal Proceedings From time to time, the Company may be involved in legal proceedings arising in the ordinary course of business. In June 2026, a former employee filed a whistleblower retaliation complaint with the Occupational Safety and Health Administration (OSHA) under Sarbanes-Oxley Act (SOX), 18 U.S.C. § 1514A. The claimant alleges they were wrongfully terminated after reporting alleged governance and honesty in shareholder relations. The Company is cooperating with OSHA’s ongoing investigation, denies all allegations and intends to vigorously defend against these allegations. At this preliminary stage, the outcome is uncertain. Although the Company cannot predict the ultimate outcome of this matter, based on currently available information, management cannot estimate the possible loss or range of loss because such amount cannot be reasonably estimated. Management does not believe that the ultimate resolution of this matter will have a material adverse effect on the Company’s consolidated financial position, results of operations, or cash flows.

P84M

3577

0.02

In January 2020, the Company entered into a lease amendment to extend the lease term through November of 2026

42500

2434

P63M

2400

0.025

2950

14000

8420

0.025

The lease will terminate on June 30, 2033

P5Y

14000

3794

843783

149125

314768

The following is a maturity analysis of the annual undiscounted cash flows of the operating lease liabilities as of June 30, 2026: SCHEDULE OF MATURITY OF ANNUAL UNDISCOUNTED OPERATING LEASE LIABILITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_495_20260630_zuYwFgl34nuj" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPz27w_zS7fcmF5qHAg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: left">2027</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">38,654</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPz27w_zyTXzfjY4WR2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2028</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_pp0p0_maLOLLPz27w_znFQ7c0Y9Dcj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">2029</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_pp0p0_maLOLLPz27w_zZu3ekr0eaN6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">2030</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--LesseeOperatingLeaseLiabilityPaymentsDueAfterYearThree_iI_pp0p0_maLOLLPz27w_z09QxqiE9qu1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Thereafter</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPz27w_zk0rxcuRwlv7" style="vertical-align: bottom; background-color: White"> <td>Total</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">38,654</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_pp0p0_di_maLOLLPzuI9_zICOmPH1nOkh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Less: amount representing interest</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseLiability_iI_pp0p0_maLOLLPzuI9_zth9QDAAR4ok" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Total</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">38,654</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

38654

the extended lease terms to November 7, 2026, and March 2027

0.0320

38654

P0Y7M6D

SCHEDULE OF BASE RENT LEASE PAYMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_496_20260630_zIiCFNsLGJY8" style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_406_ecustom--OperatingLeaseLiabilityGross_iI_pp0p0_zXmr9vnCaqjj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 80%; text-align: justify">Present value of future base rent lease payments</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">38,654</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--BaseRentPaymentsIncludedInPrepaidExpenses_iI_pp0p0_zd7FI2E9gvg3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 1pt">Base rent payments included in prepaid expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_ecustom--OperatingLeaseLiabilities_iI_pp0p0_zXHY9q5wMcOk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Present value of future base rent lease payments – net</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">38,654</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> 38654 38654 As of June 30, 2026 and March 31, 2026, operating lease right-of-use assets and operating lease liabilities were classified as follows: SCHEDULE OF LEASE CURRENT AND NON-CURRENT ASSETS AND LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20260630_znKW2NpMjfJc" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20260331_zUXtUVoAGxYf" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">March 31, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_403_ecustom--OperatingLeaseRightofuseCurrentAsset_iI_pp0p0_zm4saLOvzHOf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: justify; padding-bottom: 1pt">Operating lease right-of-use asset</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">38,654</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1pt solid; width: 16%; text-align: right">54,711</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseRightOfUseAsset_iI_pp0p0_ze6NgpRdAIVj" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Total operating lease assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38,654</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,711</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityCurrent_iI_pp0p0_zCVUdBRZfhXf" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify">Operating lease current liability</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38,654</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,711</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_zvSsNVnUbyti" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: justify; padding-bottom: 1pt">Operating lease non-current liability</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_402_ecustom--OperatingLeaseLiabilities_iI_pp0p0_z49mXNtcZ6G3" style="vertical-align: bottom; background-color: White"> <td style="text-align: justify; padding-bottom: 2.5pt">Total operating lease liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">38,654</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">54,711</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 38654 54711

38654

54711

38654

54711

38654 54711

NOTE 12 – GOING CONCERN The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company incurred a net loss $1,613,888 for the three months ended June 30, 2026, had net cash used in operating activities of $965,779 for the same period, and has an accumulated deficit of $103,051,394 on June 30, 2026. These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these consolidated financial statements are issued. Management’s plans to address these conditions include continuing efforts to improve operating results, reduce operating costs, increase revenues, and obtain additional capital through debt and/or equity financing arrangements. The Company has historically relied on external financing to fund its operations and expects to continue to seek additional financing as needed. There can be no assurance that the Company will be successful in achieving profitable operations, securing additional financing on acceptable terms, or successfully implementing its business plan. Accordingly, management has concluded that substantial doubt about the Company’s ability to continue as a going concern is not alleviated. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

-1613888

-965779

-103051394

NOTE 13 – STOCKHOLDERS’ EQUITY Equity Incentive Plan On July 10, 2020, our Board of Directors unanimously approved the PetVivo Holdings, Inc “2020 Equity Incentive Plan” (the “2020 Plan”), which authorized the issuance of up to <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20200710__us-gaap--TypeOfArrangementAxis__custom--TwoThousandAndTwentyEquityIncentivePlanMember_zFKev03DahXi">1,000,000 shares of our common stock as awards under the 2020 Plan, subject to approval by our stockholders at the Annual Meeting of Stockholders held on September 22, 2020, when it was approved by our stockholders and became effective. On October 14, 2022, the stockholders of the Company approved the PetVivo Holdings, Inc. Amended and Restated 2020 Equity Incentive Plan (the “Amended Plan”), which increased the number of shares of the Company’s common stock which may be granted under the Amended Plan from 1,000,000 to <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pid_c20221014__us-gaap--TypeOfArrangementAxis__custom--AmendedPlanMember_zAtoPBjw3TR8" title="Number of shares of common stock authorized for issuance">3,000,000. Unless sooner terminated by the Board, the Amended Plan will terminate at midnight on July 10, 2030. The Amended Plan is administered by the Compensation Committee of our Board of Directors (the “Committee”), which has full power and authority to determine when and to whom awards will be granted, and the type, amount, form of payment, any deferral payment, and other terms and conditions of each award. Subject to provisions of the Amended Plan, the Committee may amend or waive the terms and conditions, or accelerate the exercisability, of an outstanding award. The Committee also has the authority to interpret and establish rules and regulations for the administration of the Amended Plan. In addition, the Board of Directors may also exercise the powers of the Committee. The number of shares available to grant under the Amended Plan was <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20260630__us-gaap--TypeOfArrangementAxis__custom--AmendedPlanMember_zcDQ4ROWcOba" title="Number of shares available to grant">0 shares at June 30, 2026. Sale of Common Stock In March 2026, the Company entered into a private placement with an over ten percent shareholder, pursuant to which it agreed to sell <span id="xdx_909_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260301__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zfbZMngtlT2g" title="Sale of stock">1,250,000 shares of restricted common stock at a purchase price of $<span id="xdx_90A_eus-gaap--SaleOfStockPricePerShare_iI_c20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zWtGTAp4Xuki" title="Sale of stock price per shares">0.80 per share for aggregate proceeds of $<span id="xdx_90B_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20260301__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zLCBRojAUhol" title="Sale of stock, value">1,000,000. As of March 31, 2026, the Company had received $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20260301__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z9iHTZbwwOFh" title="Proceeds from sale of stock">400,000 of the purchase price and recorded the remaining $<span id="xdx_90F_ecustom--ProceedsFromSubscriptionReceivable_c20260301__20260331__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_ze4ezv9hvMPh" title="Subscription receivable">600,000 as a subscription receivable pursuant to an enforceable subscription agreement. The transaction was recorded as common stock to be issued and a subscription receivable at March 31, 2026. The remaining $600,000 was received on April 20, 2026. In June 2026, the Company entered into a private placement with an over ten percent shareholder, pursuant to which it agreed to sell <span id="xdx_907_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_c20260601__20260630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zHx9WtXVdulh">1,875,000 shares of restricted common stock at a purchase price of $0.80 per share for aggregate proceeds of $<span id="xdx_900_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20260601__20260630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zOHBLlTb6v4c">1,500,000. As of June 30, 2026, the Company had received $<span id="xdx_909_eus-gaap--ProceedsFromIssuanceOrSaleOfEquity_c20260601__20260630__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zalPWzO0Worc">150,000 of the purchase price pursuant to the subscription agreement for the issuance of 187,500 shares of common stock. The terms allow for 30-day extensions with the extended maturity date of September 15, 2026. Preferred Stock On March 26, 2025, the Company entered into a Subscription Agreement to receive <span id="xdx_904_eus-gaap--PreferredStockSharesIssued_iI_c20250326__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zSr1LVlKmUPg" title="Preferred stock, shares issued">5,000,000 shares of Series B Preferred Stock. The Company initially received $<span id="xdx_90D_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20250326__20250326__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zObeXGubsiF4" title="Proceeds from issuance of preferred stock">600,000 of proceeds on March 26, 2025, with the investor receiving an option to invest the remaining $<span id="xdx_906_eus-gaap--ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_c20250326__20250326__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--InvestorMember_zwrpYoA7cU68" title="Proceeds from issuance of preferred stock">4,400,000 pursuant to the same terms and conditions, which was fully received and funded on June 24, 2025. <span id="xdx_905_eus-gaap--ConvertiblePreferredStockTermsOfConversion_c20250326__20250326__us-gaap--TypeOfArrangementAxis__custom--SubscriptionAgreementsMember_zuk0bQFmN0h7" title="Preferred stock, convertible, terms">Series B Preferred Stock is entitled to receive a specific dividend in an annual amount equal to Ten Percent (10%) of the total amount paid to secure the Series B Convertible Preferred Stock. The dividend shall be paid to the holder by the Company in quarterly payments of Common Stock. The amount of shares pursuant to the dividend shall be calculated by dividing the total quarterly dividend payment by the greater of i) the volume weighted average price of the common stock for the prior trading ten (10) day period from the date the quarterly dividend is owed, or ii) fifty cents ($0.50). Also, non-cumulative dividends may be paid when, and if declared by the Company’s board of directors. Total dividends declared at June 30, 2026 and March 31, 2026 were $125,000 and $403,603, respectively. Upon any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, no distributions of available funds and assets will be made to the holders of Common Stock until the holders of Series B Preferred Stock and Series A Preferred Stock receive a per share amount equal to the original issue price. Common Stock During the three months ended June 30, 2026, the Company issued 1,744,326 shares of common stock as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.35in">i)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">937,500 shares in April 2026 and June 2026 in connection with the sale of stock at a price of $0.80 per share in exchange for proceeds of $750,000 recorded against common stock. </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">ii)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_909_eus-gaap--StockIssuedDuringPeriodSharesIssuedForServices_c20260601__20260630__srt--TitleOfIndividualAxis__custom--ServiceProviderMember_zLiqofNqvGc1" title="Stock issued for services, shares">200,000 shares in June 2026 to a service provider for consulting services fair valued based on the market price on the date of grant of $160,000. The Company will expense these shares on a monthly bases through September 2026.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">iii)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">368,152 shares to employees in April 2026 to June 2026 for performance services fair valued at $280,475 based on the market price at date of grant and expensed in the same period that they were issued.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">iv)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span id="xdx_901_ecustom--StockIssuedDuringPeriodSharesConversionOfAccruedDividends_c20260401__20260430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zghnP1m3VQvj" title="Issuance of shares">176,174 shares in April 2026, fair valued at $<span id="xdx_907_ecustom--StockIssuedDuringPeriodValueConversionOfAccruedDividends_c20260401__20260430__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zWFZPWTwV5Hf" title="Fair value of stock">125,000, for conversion of $125,000 of accrued dividends on Series B Preferred Stock.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">v)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">62,500 shares in April 2026 to the board of directors for advisory services and compensation fair valued at $42,000 based on the market price date of grant.</td></tr> </table> The Company has issued shares of common stock to providers of investor relations services. The value of these shares are reported as a prepaid expense and are amortized to expense over the contractual life of the respective consulting agreements. The amortization of stock issued for services was $51,467 and $40,420 for the three months ended June 30, 2026, and 2025, respectively. Stock Options Stock options issued to employees and directors typically vest over <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dc_c20260401__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zHkmyDHmPIR7" title="Vesting period">three years (one year for directors) and have a contractual term of <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dc_c20250401__20260331__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zOjSECSuMQA4" title="Vesting period">seven years. Stock-based compensation expense for stock options was $0 and $8,264 for the three months ended June 30, 2026, and 2025, respectively. As of June 30, 2026, all outstanding options were fully vested; therefore, there was <span id="xdx_90E_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pp0p0_do_c20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zXPLDO9baTGj" title="Unrecognized stock option expense">no unrecognized stock option expense. No stock options were granted during the three months ended June 30, 2026; therefore, no weighted-average assumptions are presented for the period. Stock option activity for the three months ended June 30, 2026 is as follows: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- Average Exercise Price Per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Weighted- Average Remaining Contractual Life</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value (1)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-weight: bold; text-align: left">Balance at March 31, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20260401__20260630_z1akSyxERxa" style="width: 11%; text-align: right" title="Options Outstanding, Beginning">35,954</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260401__20260630_zgZz2DZYQ121" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share, Beginning">1.06</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 13%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250401__20260331_ziB53lVM2m2k" title="Weighted Average Remaining Contractual Life">0.75 years</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260401__20260630_fKDEp_zfq1n2j69Cug" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Beginning"> -</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260401__20260630_zyIKgSkni7p7" style="text-align: right" title="Options Outstanding, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260401__20260630_zJShTAV09bKh" style="text-align: right" title="Weighted-Average Exercise Price Per Share, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20260401__20260630_zRxSLC2fvEF1" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20260401__20260630_zn3eFWqC8woc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price Per Share, Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Balance at June 30, 2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20260401__20260630_zYrW2XT9MUS4" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Ending">35,954</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260401__20260630_zbYLSNn10FTi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Per Share, Ending">1.06</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260401__20260630_zwhJ0AHywea" title="Weighted Average Remaining Contractual Life">0.75 years</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260401__20260630_fKDEp_z1ofcrqLgJX1" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Ending">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Options exercisable at June 30, 2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630_zey4XzOCOR95" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Options exercisable">35,954</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20260630_z9iLFQEzrr" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price Per Share, Options exercisable">1.06</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260401__20260630_zVMWs2zy0Ire" title="Weighted Average Remaining Contractual Life, Options Exercisable">0.75 years</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20260401__20260630_fKDEp_ziFodrbXuLk8" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Options Exercisable">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCXYFlBJNqm4" title="Share price">0.84 for the Company’s common stock on June 30, 2026 and the closing stock price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--SharePrice_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZf8DxceXMLh" title="Share price">0.70 for the Company’s common stock on March 31, 2026.</td></tr> </table> Warrants During the three months ended June 30, 2026, the Company issued warrants to purchase an aggregate of <span id="xdx_90B_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260630__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember_zni7nPvrfn2i" title="Warrants to purchase common stock">75,000 shares of common stock in connection with a consulting agreement with a fair value of $56,250 for the life of the warrants. The fair value of the warrants were recorded as $2,050 for the three months ending June 30, 2026. These warrants have a term of 3 years. The exercise strike price is $0.75 per share. <p id="xdx_897_ecustom--ScheduleOfShareBasedPaymentAwardNonEquityOptionsValuationAssumptionsTableTextBlock_z8T0vMk6QtRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">These fair value of the warrants issued was estimated using the Black-Scholes valuation model with the following assumptions: SCHEDULE OF WARRANT'S USING BLACK-SCHOLES VALUATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">Three Months Ended</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Year Ended</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">June 30, 2026</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">March 31, 2026</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Stock price on valuation date</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">0.74</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">0.70 - $1.15</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Exercise price</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcqH6hqMIje3" title="Exercise price">0.75 </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z998uAmHmfRe" title="Exercise price">0.75 - $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zjCpko7lLSyk" title="Exercise price">1.10</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Term (years)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCRDYGenHdW7" title="Term (years)">3.0</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zQdD12aCMq8f" title="Term (years)">2.0 –<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zIuk0C5vZEp8" title="Term (years)"> 3.0</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziqZ7V0Sx6O1" title="Volatility">105.7 </td> <td style="font: 10pt Times New Roman, Times, Serif">%</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zY02Iq1bxZK5" title="Volatility, minimum">106.1 –<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5Yi5r9L8zsj" title="Volatility, maximum"> 119.3</td> <td style="font: 10pt Times New Roman, Times, Serif">% </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Risk-free rate</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdNwTbK7hEb2" title="Risk-free rate">4.14</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeiCpv8jOufc" title="Risk-free rate, minimum">3.72% – <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zELT1Osjr4xb" title="Risk-free rate, maximum">3.81</td> <td style="font: 10pt Times New Roman, Times, Serif">% </td></tr> </table> A summary of warrant activity for three months ended June 30, 2026 is as follows: SCHEDULE OF WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term (in years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- Average Exercisable Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-weight: bold; text-align: justify">Outstanding, March 31, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zz9wp6HTDSAj" style="width: 11%; text-align: right" title="Number of Warrants, Outstanding, balance">15,999,081</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhwccsTrAUE7" style="width: 11%; text-align: right" title="Weighted-Average Exercise Price, Outstanding, Beginning balance">2.26</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbigVFbH5bx" title="Weighted-Average Remaining Contractual Life (Years), Outstanding">1.58</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iS_pid_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zw5NHEA7dtwg" style="width: 11%; text-align: right" title="Weighted-Average Exercisable Price, Beginning balance">2.26</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify">Granted and issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zozBnaBLWBqa" style="text-align: right" title="Number of Warrants, Outstanding, Granted and issued">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxLOGIagrVt3" style="text-align: right" title="Weighted-Average Exercise Price, Outstanding, Granted and issued">0.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedAndIssuedWeightedAverageRemainingContractualTerm_dtY_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaygfe07OYO9" title="Weighted-Average Remaining Contractual Life (Years), Granted and issued">3.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedAndIssuedWeightedAverageExercisablePrice_pid_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkbo3h0lOF2" style="text-align: right" title="Weighted-Average Exercisable Price, Granted and issued">0.75</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJ72vop3W0oa" style="text-align: right" title="Number of Warrants, Outstanding, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt5IGUn77p16" style="text-align: right" title="Weighted-Average Exercise Price, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXqCClVbOLp5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Outstanding, Expired">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice_iN_di_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxdJDvueWLp6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Outstanding, Expired">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Outstanding, June 30, 2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYASsOjHSZSk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Outstanding, balance">16,074,081</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbkos2rGIr67" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Outstanding, balance">2.25</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8Zig6dnzm75" title="Weighted-Average Remaining Contractual Life (Years), Outstanding">1.49</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_pid_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRWSBC6hKJ59" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercisable Price, balance">2.25</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> Stock-based compensation expense for warrants was $132,133 and $74,024 for the three months ended June 30, 2026, and 2025, respectively. At June 30, 2026, there was $1,430,601 of future unrecognized warrant expense, to be expensed quarterly over the remaining life of the warrants, over the next 27 months.

1000000

3000000

1250000

0.80

1000000

400000

600000

1875000

0.80

1500000

150000

187500

5000000

600000

4400000

Series B Preferred Stock is entitled to receive a specific dividend in an annual amount equal to Ten Percent (10%) of the total amount paid to secure the Series B Convertible Preferred Stock. The dividend shall be paid to the holder by the Company in quarterly payments of Common Stock. The amount of shares pursuant to the dividend shall be calculated by dividing the total quarterly dividend payment by the greater of i) the volume weighted average price of the common stock for the prior trading ten (10) day period from the date the quarterly dividend is owed, or ii) fifty cents ($0.50).

125000

403603

1744326

937500

0.80

750000

200000

160000

368152

280475

176174 125000

125000

62500

42000

51467 40420

P3Y

P7Y

8264

Stock option activity for the three months ended June 30, 2026 is as follows: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: left"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Options Outstanding</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- Average Exercise Price Per Share</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: center">Weighted- Average Remaining Contractual Life</td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Aggregate Intrinsic Value (1)</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-weight: bold; text-align: left">Balance at March 31, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20260401__20260630_z1akSyxERxa" style="width: 11%; text-align: right" title="Options Outstanding, Beginning">35,954</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260401__20260630_zgZz2DZYQ121" style="width: 11%; text-align: right" title="Weighted Average Exercise Price Per Share, Beginning">1.06</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 13%; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250401__20260331_ziB53lVM2m2k" title="Weighted Average Remaining Contractual Life">0.75 years</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260401__20260630_fKDEp_zfq1n2j69Cug" style="width: 11%; text-align: right" title="Aggregate Intrinsic Value, Beginning"> -</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260401__20260630_zyIKgSkni7p7" style="text-align: right" title="Options Outstanding, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c20260401__20260630_zJShTAV09bKh" style="text-align: right" title="Weighted-Average Exercise Price Per Share, Granted">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Cancelled</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_iN_di_c20260401__20260630_zRxSLC2fvEF1" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20260401__20260630_zn3eFWqC8woc" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price Per Share, Cancelled">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"> </td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Balance at June 30, 2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20260401__20260630_zYrW2XT9MUS4" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Ending">35,954</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260401__20260630_zbYLSNn10FTi" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Exercise Price Per Share, Ending">1.06</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260401__20260630_zwhJ0AHywea" title="Weighted Average Remaining Contractual Life">0.75 years</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260401__20260630_fKDEp_z1ofcrqLgJX1" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Ending">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: right"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1pt">Options exercisable at June 30, 2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_c20260630_zey4XzOCOR95" style="border-bottom: Black 1pt solid; text-align: right" title="Options Outstanding, Options exercisable">35,954</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_c20260630_z9iLFQEzrr" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price Per Share, Options exercisable">1.06</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="text-align: right; padding-bottom: 1pt"><span id="xdx_90D_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260401__20260630_zVMWs2zy0Ire" title="Weighted Average Remaining Contractual Life, Options Exercisable">0.75 years</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_980_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20260401__20260630_fKDEp_ziFodrbXuLk8" style="border-bottom: Black 1pt solid; text-align: right" title="Aggregate Intrinsic Value, Options Exercisable">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">(1)</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_90B_eus-gaap--SharePrice_iI_pid_c20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zCXYFlBJNqm4" title="Share price">0.84 for the Company’s common stock on June 30, 2026 and the closing stock price of $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFNUT0NLIE9QVElPTiBBQ1RJVklUWSAoRGV0YWlscykgKFBhcmVudGhldGljYWwpAA__" id="xdx_902_eus-gaap--SharePrice_iI_pid_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zZf8DxceXMLh" title="Share price">0.70 for the Company’s common stock on March 31, 2026.</td></tr> </table>

35954

1.06

P0Y9M

35954

1.06

P0Y9M

35954

1.06

P0Y9M

0.84

0.70

75000

56250

2050

P3Y

0.75

<p id="xdx_897_ecustom--ScheduleOfShareBasedPaymentAwardNonEquityOptionsValuationAssumptionsTableTextBlock_z8T0vMk6QtRj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">These fair value of the warrants issued was estimated using the Black-Scholes valuation model with the following assumptions: SCHEDULE OF WARRANT'S USING BLACK-SCHOLES VALUATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif">Three Months Ended</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center">Year Ended</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">June 30, 2026</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td colspan="2" style="border-bottom: black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">March 31, 2026</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 60%">Stock price on valuation date</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">0.74</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 2%"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%">$</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right">0.70 - $1.15</td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Exercise price</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zcqH6hqMIje3" title="Exercise price">0.75 </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">$</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_z998uAmHmfRe" title="Exercise price">0.75 - $<span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zjCpko7lLSyk" title="Exercise price">1.10</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Term (years)</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zCRDYGenHdW7" title="Term (years)">3.0</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zQdD12aCMq8f" title="Term (years)">2.0 –<span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zIuk0C5vZEp8" title="Term (years)"> 3.0</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif">Volatility</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_ziqZ7V0Sx6O1" title="Volatility">105.7 </td> <td style="font: 10pt Times New Roman, Times, Serif">%</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_pid_dp_uPure_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zY02Iq1bxZK5" title="Volatility, minimum">106.1 –<span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_pid_dp_uPure_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5Yi5r9L8zsj" title="Volatility, maximum"> 119.3</td> <td style="font: 10pt Times New Roman, Times, Serif">% </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif">Risk-free rate</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_uPure_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zdNwTbK7hEb2" title="Risk-free rate">4.14</td> <td style="font: 10pt Times New Roman, Times, Serif">%</td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_dp_uPure_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeiCpv8jOufc" title="Risk-free rate, minimum">3.72% – <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_dp_uPure_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zELT1Osjr4xb" title="Risk-free rate, maximum">3.81</td> <td style="font: 10pt Times New Roman, Times, Serif">% </td></tr> </table>

0.74

0.70

1.15

0.75

1.10

P3Y

P2Y

P3Y

1.057

1.061

1.193

0.0414

0.0372

0.0381

A summary of warrant activity for three months ended June 30, 2026 is as follows: SCHEDULE OF WARRANT ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- Average Exercise Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Term (in years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted- Average Exercisable Price</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: justify"> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td><td> </td> <td colspan="2" style="text-align: right"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%; font-weight: bold; text-align: justify">Outstanding, March 31, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zz9wp6HTDSAj" style="width: 11%; text-align: right" title="Number of Warrants, Outstanding, balance">15,999,081</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zhwccsTrAUE7" style="width: 11%; text-align: right" title="Weighted-Average Exercise Price, Outstanding, Beginning balance">2.26</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20250401__20260331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbigVFbH5bx" title="Weighted-Average Remaining Contractual Life (Years), Outstanding">1.58</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iS_pid_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zw5NHEA7dtwg" style="width: 11%; text-align: right" title="Weighted-Average Exercisable Price, Beginning balance">2.26</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify">Granted and issued</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zozBnaBLWBqa" style="text-align: right" title="Number of Warrants, Outstanding, Granted and issued">75,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageExercisePrice_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxLOGIagrVt3" style="text-align: right" title="Weighted-Average Exercise Price, Outstanding, Granted and issued">0.75</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedAndIssuedWeightedAverageRemainingContractualTerm_dtY_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zaygfe07OYO9" title="Weighted-Average Remaining Contractual Life (Years), Granted and issued">3.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedAndIssuedWeightedAverageExercisablePrice_pid_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zkbo3h0lOF2" style="text-align: right" title="Weighted-Average Exercisable Price, Granted and issued">0.75</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJ72vop3W0oa" style="text-align: right" title="Number of Warrants, Outstanding, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedInPeriodWeightedAverageExercisePrice_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zt5IGUn77p16" style="text-align: right" title="Weighted-Average Exercise Price, Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Expired</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_iN_di_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXqCClVbOLp5" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Outstanding, Expired">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirationsInPeriodWeightedAverageExercisePrice_iN_di_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxdJDvueWLp6" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Outstanding, Expired">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold; text-align: justify; padding-bottom: 1pt">Outstanding, June 30, 2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zYASsOjHSZSk" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Warrants, Outstanding, balance">16,074,081</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_988_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zbkos2rGIr67" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercise Price, Outstanding, balance">2.25</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8Zig6dnzm75" title="Weighted-Average Remaining Contractual Life (Years), Outstanding">1.49</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice_iE_pid_c20260401__20260630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRWSBC6hKJ59" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted-Average Exercisable Price, balance">2.25</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> </table>

15999081

2.26 P1Y6M29D 2.26

75000

0.75 P3Y 0.75

16074081

2.25 P1Y5M26D 2.25

132133

74024

1430601

NOTE 14 – SEGMENT REPORTING The Company manages the business activities on a consolidated basis and operates in <span id="xdx_905_eus-gaap--NumberOfReportableSegments_dc_uSegment_c20260401__20260630__us-gaap--StatementBusinessSegmentsAxis__custom--SingleReportableSegmentMember_zGsKVtIaKmM5" title="Number of reportable segments">one reportable segment. The Company’s reportable segment is an emerging biomedical device company focused on the manufacturing, commercialization, and licensing of innovative medical devices and therapeutics for animals. The segment is animal health products. As the Company has one reportable segment, sales and marketing, research and development, including clinical trial expenses and general and administrative expenses are equal to consolidated results. Financial results for the Company’s reportable segment have been prepared using a management approach, which is consistent with the basis and manner in which financial information is evaluated by the Company’s Chief Operating Decision Maker (“CODM”) in allocating resources and in assessing performance. The Company’s CODM is the Chief Executive Officer. The measurement of segment profit or loss that the CODM uses to evaluate the performance of the Company’s segment is net operating loss attributable to animal health. The CODM reviews financial budgets and actual results to assess performance and allocate resources, and makes strategic decisions related to headcount and other expenditures on a consolidated basis. SCHEDULE OF SEGMENT INFORMATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260401__20260630_zuN8xtfRO1Ti" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20250401__20250630_z4FO8md51RG8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Three Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zRX9Scd4Mpeh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">NET REVENUE</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">337,572</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">297,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--CostOfGoodsAndServicesSold_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zVF6eeqn0jmd" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Cost of Sales</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">114,255</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">110,774</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--GrossProfit_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zHOPb0jUvoC5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross Profit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">223,317</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">186,726</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingExpensesAbstract_iB_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zTlowm6fdoE7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">OPERATING EXPENSES</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--SellingAndMarketingExpense_i01_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zle9NZmpMfBc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Sales and marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">631,305</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">621,712</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_i01_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z4IZbiltJWf7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">233,419</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">340,513</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--GeneralAndAdministrativeExpense_i01_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zhUpYzNFqrx7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">967,442</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,068,818</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingExpenses_i01T_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z9gLkA4KhqB6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,832,166</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,031,043</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_i01T_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zkkrGfJCBsai" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">NET OPERATING LOSS</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,608,849</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,844,317</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

SCHEDULE OF SEGMENT INFORMATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 80%; margin-right: auto"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260401__20260630_zuN8xtfRO1Ti" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20250401__20250630_z4FO8md51RG8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="6" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">For the Three Months Ended</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_401_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zRX9Scd4Mpeh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">NET REVENUE</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">337,572</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">297,500</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--CostOfGoodsAndServicesSold_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zVF6eeqn0jmd" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt">Cost of Sales</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">114,255</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">110,774</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--GrossProfit_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zHOPb0jUvoC5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross Profit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">223,317</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">186,726</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--OperatingExpensesAbstract_iB_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zTlowm6fdoE7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">OPERATING EXPENSES</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--SellingAndMarketingExpense_i01_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zle9NZmpMfBc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Sales and marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">631,305</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">621,712</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_eus-gaap--ResearchAndDevelopmentExpense_i01_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z4IZbiltJWf7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">233,419</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">340,513</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--GeneralAndAdministrativeExpense_i01_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zhUpYzNFqrx7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">General and administrative</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">967,442</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,068,818</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingExpenses_i01T_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_z9gLkA4KhqB6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Total operating expenses</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,832,166</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">2,031,043</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_i01T_hsrt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember_zkkrGfJCBsai" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">NET OPERATING LOSS</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,608,849</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(1,844,317</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr> </table>

337572

297500

114255

110774

223317

186726

631305

621712

233419

340513

967442

1068818

1832166

2031043

-1608849

-1844317

NOTE 15 – INVESTMENTS IN EQUITY SECURITIES In March 2025, the Company signed a strategic alliance agreement with Digital Landia Corp, a pioneer in Agentic AI solutions for a Pet AI platform. Under the agreement, PetVivo exchanged $<span id="xdx_90C_eus-gaap--EquityMethodInvestments_iI_c20250331__us-gaap--TypeOfArrangementAxis__custom--StrategicAllianceAgreementMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--DigitalLandiaCorpMember_z62F7LMDRDic">150,000 in <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesConversionOfUnits_c20250301__20250331__us-gaap--StatementClassOfStockAxis__custom--RestrictedCommonStockMember__us-gaap--TypeOfArrangementAxis__custom--StrategicAllianceAgreementMember_z94ug4ipGr12">230,770 shares of restricted common stock for an approximate 2% equity stake in Digital Landia, thereby becoming the Platinum Sponsor of the Pet AI community. PetVivo will also receive economic benefits from 3 million Digital Landia tokens expected to be launched upon proper market conditions. As an exclusive advertiser for lameness and joint affliction medical device products, as well as regenerative therapeutic products, PetVivo’s products, our SPRYNG® with OsteoCushion® Technology, will be promoted to users when the AI detects joint related afflictions or other degenerative afflictions in pets. Further with the strategic alliance agreement, the Company issued <span id="xdx_900_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_iI_c20250331__dei--LegalEntityAxis__custom--DigitalLandiaHoldingCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z91oCFWJP3c8">1,000,000 warrants to Digital Landia fair valued at $<span id="xdx_902_eus-gaap--FairValueConcentrationOfRiskEquityMethodInvestments_iI_c20250331__dei--LegalEntityAxis__custom--DigitalLandiaHoldingCorpMember__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zxJB3r9pNQV7">35,197. The Company holds equity investments in Digital Landia Corp, a privately held entity, that does not have readily determinable fair values for its common stock. The Company elected the measurement alternative for eligible non-marketable equity securities under ASC 321-10-35-2. These investments are carried at historical cost and adjusted upward or downward for observable price changes in orderly transactions for the identical or similar investment of the same issuer, less any impairment. As of the date of this report, as of June 30, 2026, the Company continues to use the $<span id="xdx_90D_eus-gaap--EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_iI_c20260630__dei--LegalEntityAxis__custom--DigitalLandiaHoldingCorpMember_zNCKzElpEqu6" title="Equity securities without readily determinable fair value">150,000 historical cost of the PetVivo shares issued in exchange for $150,000 of the Digital Landia shares. There has been no observable price changes or impairments, so the carrying amount of $<span id="xdx_90E_eus-gaap--EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_iI_c20260630__dei--LegalEntityAxis__custom--DigitalLandiaHoldingCorpMember_zh2jmoVxOQCf" title="Equity securities without readily determinable fair value">150,000 remains at its historical cost. As of June 30, 2026, the $150,000 investment has been reclassified from a current asset to a noncurrent (long-term) asset.

150000

230770

0.02

3000000

1000000

35197

150000

NOTE 16 – INCOME TAXES No income tax benefit has been recorded for the periods ended June 30, 2026, and 2025, as the Company has incurred operating losses and maintains a full valuation allowance against its net deferred tax assets. Interim Effective Tax Rate: The Company’s effective tax rate was 0.0% for the three months ended June 30, 2026 and 2025, compared with the U.S. federal statutory income tax rate of 21.0%. The difference between the Company’s effective tax rate and the U.S. federal statutory rate was primarily attributable to the valuation allowance recorded against the Company’s deferred tax assets. Discrete Items: There have been no discrete items in the period ending June 30, 2026. Uncertain Tax Positions: There have been no material changes to the total amount of unrecognized tax benefits or our position on uncertain tax standards since June 30, 2026.

0.000

0.210

NOTE 17 – SUBSEQUENT EVENTS In accordance with ASC 855, the following information below are subsequent transactions from the end of the June 30, 2026 reporting period to the date of this filing on August 14, 2026. In July 2026, the Company issued <span id="xdx_907_eus-gaap--ConversionOfStockSharesConverted1_c20260701__20260731__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zban5gnNsP2k" title="Conversion of shares">156,250 shares of restricted stock for the conversion of accrued dividends on Series B Preferred Stock valued at $<span id="xdx_908_eus-gaap--ConversionOfStockAmountConverted1_c20260701__20260731__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesBPreferredStockMember_zKyF6XheE63k" title="Conversion of value">125,000. In July 2026, the Company issued <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20260701__20260731__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z0AWAJbT0A8h" title="Common stock issued to employees for compensation, shares">200,000 shares of restricted stock to employees for performance bonuses valued at market on the date of grant of $<span id="xdx_906_eus-gaap--StockIssued1_c20260701__20260731__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--EmployeeStockMember_z9xWdgeai8I7" title="Common stock issued to employees for compensation, value">160,000 and expense in the current period. On July 9, 2026, the Company received proceeds of $100,000 on a promissory note with a maturity date of January 9, 2027 and an accrued interest rate of 6% per annum with no conversion provisions. On July 24, 2026, the Company terminated the VetStem, Inc. licensing agreement. With the licensing termination, the Company is obligated to pay a fee of $75,000 in lieu of any liabilities to be waived and the return of any remaining PRP inventory on July 24, 2026. On July 27, 2026, the Company received proceeds of $130,000 on a promissory note with a maturity date of July 27, 2027 and an accrued interest rate of 6% per annum with no conversion provisions. Between August 7 through August 11, 2026, the Company received proceeds of $150,000 on a promissory note with a maturity date of August 7, 2027 and an accrued interest rate of 10% per annum with no conversion provisions. On August 11, 2026, the Company received proceeds of $50,000 on a promissory note with a maturity date of November 11, 2026 and an accrued interest rate of 10% per annum with no conversion provisions. On August 13, 2026, <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensation_c20260813__20260813__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zGh5RYMzve8e" title="Common stock issued to employees for compensation, shares">2,875,000 of the February 9, 2022 registered tradeable warrants, trading under the ticker symbol “PETVW” expired, pursuant to the terms of the warrant.

156250

125000

200000

160000

100000

2027-01-09

0.06

75,000

130000

2027-07-27

0.06

150000

2027-08-07

0.10

50000

2026-11-11

0.10

2875000

The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the closing stock price of $0.84 for the Company’s common stock on June 30, 2026 and the closing stock price of $0.70 for the Company’s common stock on March 31, 2026.